EP1482787A4 - Cellules souches de type embryonnaire derivees de placenta mammalien post-partum, utilisations, et procedes de traitement a base de cellules de ce type - Google Patents

Cellules souches de type embryonnaire derivees de placenta mammalien post-partum, utilisations, et procedes de traitement a base de cellules de ce type

Info

Publication number
EP1482787A4
EP1482787A4 EP03739817A EP03739817A EP1482787A4 EP 1482787 A4 EP1482787 A4 EP 1482787A4 EP 03739817 A EP03739817 A EP 03739817A EP 03739817 A EP03739817 A EP 03739817A EP 1482787 A4 EP1482787 A4 EP 1482787A4
Authority
EP
European Patent Office
Prior art keywords
cells
stem cells
embryonic
stem
cord blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP03739817A
Other languages
German (de)
English (en)
Other versions
EP1482787A2 (fr
Inventor
Robert J Hariri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clarity Acquisition II LLC
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/076,180 external-priority patent/US20030032179A1/en
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Priority to EP10155478A priority Critical patent/EP2186407A1/fr
Priority to EP10184356A priority patent/EP2301343A1/fr
Priority to EP10185142A priority patent/EP2292091A1/fr
Publication of EP1482787A2 publication Critical patent/EP1482787A2/fr
Publication of EP1482787A4 publication Critical patent/EP1482787A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A61M2202/0462—Placental blood, umbilical cord blood

Definitions

  • the present invention relates to the use of embryonic-like stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells.
  • the embryonic-like stem cells can be used alone or in a mixture with other stem cell populations.
  • the embryonic-like stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow.
  • the embryonic-like stem cells and the mixed populations of embryonic-like stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation, diagnostic and research uses.
  • the embryonic-like stem cells and the mixed populations are also useful in the treatment of diseases or disorders, including vascular disease, neurological diseases or disorders, autoimmune diseases or disorders, diseases or disorders involving inflammation, and cancer or the disorders associated therewith.
  • diseases or disorders including vascular disease, neurological diseases or disorders, autoimmune diseases or disorders, diseases or disorders involving inflammation, and cancer or the disorders associated therewith.
  • the embryonic-like stem cells or mixtures including them are administered in high doses and without HLA typing.
  • Human stem cells are totipotential or pluripotential precursor cells capable of generating a variety of mature human cell lineages. This ability serves as the basis for the cellular differentiation and specialization necessary for organ and tissue development.
  • stem cells can be employed to repopulate many, if not all, tissues and restore physiologic and anatomic functionality.
  • the application of stem cells in tissue engineering, gene therapy delivery and cell therapeutics is also advancing rapidly.
  • stem cells Many different types have been characterized. For example, embryonic stem cells, embryonic germ cells, adult stem cells or other committed stem cells or progenitor cells are known. Certain stem cells have not only been isolated and characterized but have also been cultured under conditions to allow differentiation to a limited extent. A basic problem remains, however, in that obtaining sufficient quantities and populations of human stem cells which are capable of differentiating into all cell types is near impossible. Stem cells are in critically short supply. These are important for the treatment of a wide variety of disorders, including malignancies, inborn errors of metabolism, hemoglobinopathies, and immunodeficiencies. It would be highly advantageous to have a source of more embryonic stem cells.
  • stem cells from alternative sources in adequate amounts for therapeutic and research purposes is generally laborious, involving, e.g., harvesting of cells or tissues from a donor subject or patient, culturing and/or propagation of cells in vitro, dissection, etc.
  • Caplan et al. discloses human mesenchymal stem cell (hMSC) compositions derived from the bone marrow that serve as the progenitors for mesenchymal cell lineages.
  • hMSCs are identified by specific cell surface markers that are identified with monoclonal antibodies.
  • Homogeneous hMSC compositions are obtained by positive selection of adherent marrow or periosteal cells that are free of markers associated with either hematopoietic cell or differentiated mesenchymal cells.
  • WO 00/73421 entitled “Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells,” published December 7, 2000) discloses human amniotic epithelial cells derived from placenta at delivery that are isolated, cultured, cryopreserved for future use, or induced to differentiate.
  • a placenta is harvested immediately after delivery and the amniotic membrane separated from the chorion, e.g., by dissection.
  • Amniotic epithelial cells are isolated from the amniotic membrane according to standard cell isolation techniques.
  • the disclosed cells can be cultured in various media, expanded in culture, cryopreserved, or induced to differentiate.
  • amniotic epithelial cells are multipotential (and possibly pluripotential), and can differentiate into epithelial tissues such as corneal surface epithelium or vaginal epithelium.
  • epithelial tissues such as corneal surface epithelium or vaginal epithelium.
  • the drawback of such methods is that they are labor-intensive and the yield of stem cells is very low.
  • amniotic epithelial cells must be first isolated from the amnion by dissection and cell separation techniques, then cultured and expanded in vitro.
  • Umbilical cord blood (“cord blood”) is a known alternative source of hematopoietic progenitor stem cells.
  • Stem cells from cord blood are routinely cryopreserved for use in hematopoietic reconstitution, a widely used therapeutic procedure used in bone marrow and other related transplantations (see e.g., Boyse et al, U.S. 5,004,681, "Preservation of Fetal and Neonatal Hematopoietin Stem and Progenitor Cells of the Blood", Boyse et al, U.S. Patent No.
  • Patent No. 5,962,325 entitled “Three-dimensional stromal tissue cultures” issued October 5, 1999) discloses that fetal cells, including fibroblast-like cells and chondrocyte-progenitors, may be obtained from umbilical cord or placenta tissue or umbilical cord blood.
  • binding molecules with specific affinity such as a monoclonal antibody for CD34
  • a predetermined population of cells such as CD34 cells
  • stem cells Because of restrictions on the collection and use of stem cells, and the inadequate 5 numbers of cells typically collected from cord blood, stem cells are in critically short supply. Stem cells have the potential to be used in the treatment of a wide variety of disorders, including malignancies, inborn errors of metabolism, hemoglobinopathies, and immunodeficiencies. There is a critical need for a readily accessible source of large numbers of human stem cells for a variety of therapeutic and other medically related 0 purposes. The present invention addresses that need and others.
  • ALS amylotrophic lateral sclerosis
  • the present invention relates to cord blood compositions or stem or progenitor cells therefrom in which said compositions are supplemented with or contacted with embryonic- like stem cells that originate from a post-partum placenta.
  • the embryonic-like stem cells which are the subject of other applications can be used herein as a composition or a mixture with other stem or progenitor cell populations.
  • the embryonic-like stem cells may contacted with other stem or progenitor cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow.
  • the embryonic-like stem cells and the mixed populations of embryonic-like stem cells and stem or progenitor cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses.
  • populations of stem cells are mixed with populations of embryonic-like stem cells in order to supplement, augment or enhance the concentrations of pluripotent and multipotent stem cells in the stem cell populations, for example, in one embodiment, umbilical cord blood, or stem or progenitor cells therefrom, is augmented or contacted with the embryonic-like stem cells of the invention prior to administration to the patient.
  • the embryonic-like stem cells may also be administered simultaneously or sequentially with the umbilical cord blood, or cells therefrom, However, contacting the cells of each before administration is preferred.
  • the embryonic-like stem cells of the invention may be characterized by the presence of the following cell surface markers: CD 10, CD29, CD44, CD54, CD90, SH2, SH3, SH4, OCT-4 and ABC-p, and the absence of the following cell surface markers: CD34, CD38, CD45, SSEA3 and SSEA4.
  • such embryonic-like stem cells may be characterized by the presence of cell surface markers OCT-4 and APC-p.
  • Embryonic- like stem cells originating from placenta have characteristics of embryonic stem cells but are not derived from the embryo.
  • the invention encompasses mixtures of cord blood and embryonic-like stem cells isolated from a placenta that are OCT-4+ and/or ABC-p+.
  • embryonic-like stem cells are as versatile (e.g., pluripotent) as human embryonic stem cells.
  • populations of stem cells are mixed with embryonic-like stem cells that are pluripotent or multipotent.
  • embryonic-like stem cells can be isolated from the perfused placenta at different time points e.g., CD34+ /CD38+, CD34+/CD38-, and CD34-/CD38- hematopoietic cells.
  • such cells may be used to supplement populations of hematopoietic stem cells, such as those found in umbilical cord blood, according to the methods of the invention.
  • the invention also provides a composition in which a mixture of stem cells with embryonic-like stem cells is contained within one bag or container.
  • the composition is a pharmaceutically acceptable unit dose composition.
  • the invention provides a composition in which a population of stem cells and a population of embryonic-like stem cells are contained within two separate bags or containers.
  • such a "two bag" kit may be mixed prior, in particular immediately prior to, or at the time of administration to a patient in need thereof.
  • the contents of each bag may be administered separately to a patient, wherein the mixing of the two cell populations occurs in vivo, h other embodiments, the container is sealed, air tight, and sterile.
  • the present invention relates to populations of stem cells are mixed with embryonic- like stem cells.
  • stems cells that may be mixed with embryonic-like stem cells include, but are not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow.
  • the embryonic-like stem cells of the invention are mixed with umbilical cord blood.
  • the present invention also provides methods of treating a patient in need thereof by administration of a population of stem cells supplemented with embryonic-like stem cells.
  • the supplementation of the population of cord blood cells with embryonic-like stem cells occurs by mixing the stem cells and embryonic-like stem cells prior to administration of the combined or "spiked" population to the patient.
  • the supplementation of the population of stem cells with embryonic-like stem cells occurs upon administration of the supplemented population to the patient, e.g., by simultaneous administration of the cord blood cells and the embryonic-like stem cells.
  • the supplementation of the population of stem cells with embryonic- like stem cells occurs after administration of the cord blood cells to the patient, e.g., by administering the embryonic-stem cells separately from, and before or after, administration of the stem cells.
  • populations of stem cells e.g., umbilical cord blood
  • embryonic-like stem cells from the placenta have a multitude of uses, including prophylactic, therapeutic and diagnostic uses.
  • the supplemented populations of stem cells can be used for transplantation and/or to treat or prevent disease.
  • the supplemented populations of cells are used to renovate and repopulate tissues and organs, thereby replacing or repairing diseased tissues, organs or portions thereof.
  • the supplemented populations of stem cells can be used as a diagnostic to screen for genetic disorders or a predisposition for a particular disease or disorder.
  • the invention provides a method for isolating other embryonic- like and/or multipotent or pluripotent stem cells from an extract or perfusate of a exsanguinated placenta and using them to supplement populations of cord blood cells according to the methods of the invention.
  • the present invention also provides pharmaceutical compositions that comprise populations of stem cells, e.g. , umbilical cord blood cells, that have been supplemented with one or more populations of embryonic-like stem cells of the invention.
  • populations of stem cells e.g. , umbilical cord blood cells
  • the present invention provides an isolated homogenous population of human placental stem cells that has the potential to differentiate into all cell types, another embodiment, the population of human placental stem cells has the potential to differentiate into one cell type. In yet another embodiment, the population of human placental stem cells has the potential to differentiate into several different cell types. Such cells maybe used to supplement populations of stem cells, e.g., umbilical cord blood, according to the methods of the invention.
  • the invention also encompasses pharmaceutical compositions that comprise populations of hematopoietic stem cells supplemented with one or more populations of cells that have high concentrations (or larger populations) of homogenous hematopoietic stem cells including, but not limited to, CD34+ /CD38- cells; CD34-/CD38- cells, and CD133 + cells.
  • populations of hematopoietic stem cells including, but not limited to, CD34+ /CD38- cells; CD34-/CD38- cells, and CD133 + cells.
  • CD34+ /CD38- cells CD34-/CD38- cells
  • CD133 + cells CD133 + cells.
  • One or more of these cell populations can be used with, or mixed with, hematopoietic stem cells i.e., CD34+/CD38+ hematopoietic cells, obtained from umbilical cord blood or other sources, for transplantation and other uses.
  • the present invention also provides methods of mixing a population of stem, progenitor or cord blood cells, including banked or cryopreserved cord blood cells, with a population of embryonic-like stem cells.
  • the two populations are physically mixed.
  • the two populations are physically mixed and then treated with a growth factor, e.g., a cytokine and/or an interleukm, to induce cell differentiation.
  • the stem cells and/or the embryonic-like stem cells are treated with a growth factor, e.g., a cytokine and/or an interleukm, to induce cell differentiation and then physically mixed.
  • the mixed populations are treated with a growth factor to induce differentiation into a variety of cell types, hi another embodiment, the mixed populations are treated with a growth factor to induce differentiation into a particular cell type. In another embodiment, the mixed populations are treated with a growth factor to prevent or suppress differentiation into a particular cell type.
  • the culture conditions can be controlled, e.g., the mixed population of cells can be treated with a specific cocktail of cytokines or interleukins to direct or induce differentiation to a specific cell type.
  • the invention provides a method of treating a patient in need thereof comprising administration of a plurality of umbilical cord blood cells and a plurality of embryonic-like stem cells.
  • the invention provides a method of treating myelodysplasia which comprises administering umbilical cord blood cells (or stem cells isolated therefrom) and embryonic-like stem cells to a patient in need thereof.
  • the invention also relates to new uses of human placental stem cells (embryonic-like stem cells). Methods of treating or preventing disease with the compositions containing embryonic-like stem cells and other stem or progenitor cells or sources thereof are also encompassed herein. Similarly, methods of dosing such compositions are encompassed. finally, it should be noted that the compositions of the invention can contain stem or progenitor cell populations from multiple donors.
  • the invention includes the use of non- HLA matched compositions in patients as well as HLA-matched compositions, blood type matching with the patient is preferred but not required when the compositions containing both embryonic-like stem cells and stem or progenitor cells are used.
  • the term “bioreactor” refers to an ex vivo system for propagating cells, producing or expressing biological materials and growing or culturing cells tissues, organoids, viruses, proteins, polynucleotides and microorganisms.
  • the terms “cord blood” and “umbilical cord blood” are interchangeable.
  • embryonic stem cell refers to a cell that is derived from the inner cell mass of a blastocyst (e.g., a 4- to 5-day-old human embryo) and that is pluripotent.
  • embryonic-like stem cell refers to a cell that is not derived from the inner cell mass of a blastocyst.
  • an “embryonic- like stem cell” may also be referred to as a "placental stem cell,” preferably a human placental stem cell derived from a post-partum perfused placenta.
  • An embryonic-like stem cell is preferably pluripotent.
  • the stem cells which may be obtained from the placenta include embryonic-like stem cells, multipotent cells, and committed progenitor cells.
  • embryonic-like stem cells derived from the placenta may be collected from the isolated placenta once it has been exsanguinated and perfused for a period of time sufficient to remove residual cells.
  • exsanguinated refers to the removal and/or draining of substantially all cord blood o from the placenta.
  • exsanguination of the placenta can be achieved by, for example, but not by way of limitation, draining, gravity induced efflux, massaging, squeezing, pumping, etc.
  • exsanguination of the placenta may further be achieved by perfusing, rinsing or flushing the placenta with a fluid that may or may not contain agents, such as anticoagulants, to aid in the 5 exsanguination of the placenta.
  • the term to "mix” means to combine or blend into one mass or mixture; to put together into one mass so that the constituent parts are more or less homogeneous; to create or form by combining ingredients; to form by admixture, augmentation, supplementation, or commingling; or to add an ingredient or element to 0 another ingredient or element, and vice-versa.
  • perfuse refers to the act of pouring or passaging a fluid over or through an organ or tissue, preferably the passage of fluid through an organ or tissue with sufficient force or pressure to remove any residual cells, e.g., non- attached cells from the organ or tissue.
  • perfusate refers to the 5 fluid collected following its passage through an organ or tissue, hi a preferred embodiment, the perfusate contains one or more anticoagulants.
  • exogenous cell refers to a "foreign" cell, i.e., a heterologous cell (i.e., a "non-self cell derived from a source other than the placental donor) or autologous cell (i.e., a "self cell derived from the placental donor) that is-derived from an organ or tissue other than the placenta.
  • a heterologous cell i.e., a "non-self cell derived from a source other than the placental donor
  • autologous cell i.e., a "self cell derived from the placental donor
  • organoid refers to an aggregation of one or more cell types assembled in superficial appearance or in actual structure as any organ or gland of a mammalian body, preferably the human body.
  • multipotent cell refers to a cell that has the capacity to grow into any of subset of the mammalian body's approximately 260 cell types. Unlike a pluripotent cell, a multipotent cell does not have the capacity to form all of the cell types.
  • pluripotent cell refers to a cell that has complete differentiation versatility, i.e., the capacity to grow into any of the mammalian body's approximately 260 cell types.
  • a pluripotent cell can be self-renewing, and can remain dormant or quiescent within a tissue. Unlike a totipotent cell (e.g., a fertilized, diploid egg cell), an embryonic stem cell cannot usually form a new blastocyst.
  • progenitor cell refers to a cell that is committed to differentiate into a specific type of cell or to form a specific type of tissue.
  • stem cell refers to a master cell that can reproduce indefinitely to form the specialized cells of tissues and organs.
  • a stem cell is a o developmentally pluripotent or multipotent cell.
  • a stem cell can divide to produce two daughter stem cells, or one daughter stem cell and one progenitor ("transit") cell, which then proliferates into the tissue's mature, fully formed cells.
  • the “stem cell” used herein includes “progenitor cells” unless otherwise noted.
  • totipotent cell refers to a cell that is able to form a 5 complete embryo (e.g. , a blastocyst).
  • the present invention is based in part on the unexpected discovery that embryonic- like stem cells produced by the exsanguinated, perfused and/or cultured placenta are 0 pluripotent stem cells that can be readily differentiated into any desired cell type. These embryonic-like stem cells can be used to supplement, augment or enhance populations of stem cells, including, but not limited to umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow.
  • populations of stem cells are 5 mixed with populations of embryonic-like stem cells in order to supplement, augment or enhance the concentrations of pluripotent and multipotent stem cells in the stem cell populations, hi accordance with the present invention, the populations of stem cells mixed with populations of embryonic-like stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and 0 prevention of disease, and diagnostic and research uses.
  • the invention also provides a composition in which a mixture of stem cells and embryonic-like stem cells is contained within one bag or container.
  • the invention provides a composition in which a population of stem cells and a population of embryonic-like stem cells are contained within two separate bags or containers.
  • such a "two bag" composition may be mixed prior, in particular immediately prior, to or at the time of administration to a patient in need thereof.
  • the contents of each bag may be administered separately to a patient, wherein two cell populations are used adjunctively in vivo.
  • the present invention also provides methods of mixing a population of stem or progenitor cells or cord blood including banked or cryopreserved cord blood with a population of embryonic-like stem cells.
  • the two populations are physically mixed.
  • the two populations are physically mixed and then treated with a growth factor, e.g., a cytokine and/or an interleukin, to induce cell differentiation.
  • the stem cells and/or the embryonic-like stem cells are treated with a growth factor, e.g., a cytokine and/or an o interleukin, to induce cell differentiation and then physically mixed.
  • the present invention also provides methods of mixing a population of committed cells, e.g., a population of cells committed to differentiate into neurons, muscle cells, hematopoietic, vascular cells, adipocytes, chondrocytes, osteocytes, hepatocytes, pancreatic, or cardiac cells, with a population of embryonic-like stem cells.
  • a population of committed cells e.g., a population of cells committed to differentiate into neurons, muscle cells, hematopoietic, vascular cells, adipocytes, chondrocytes, osteocytes, hepatocytes, pancreatic, or cardiac cells
  • a population of embryonic-like stem cells e.g., the 5 two populations are physically mixed.
  • the two populations are physically mixed and then treated with a growth factor, e.g., a cytokine and/or an interleukin, to induce cell differentiation.
  • the committed cells and/or the embryonic-like stem cells are treated with a growth
  • embryonic-like stem cells are extracted from a drained placenta by means of a perfusion technique that utilizes either or both of the umbilical artery and the umbilical vein.
  • the placenta is preferably drained by exsanguination and collection of residual blood (e.g., residual umbilical cord blood).
  • residual blood e.g., residual umbilical cord blood
  • the 5 drained placenta is then processed in such a manner as to establish the ex vivo, natural bioreactor environment in which the resident embryonic-like stem cells within the parenchyma and extravascular space are recruited.
  • the embryonic-like stem cells migrate into the drained, empty microcirculation where, according to the methods of the invention, they are collected, preferable by washing into a collecting vessel by perfusion.
  • pluripotent or multipotent stem cells can be isolated from the perfused placenta at different time points during the perfusion, e.g., CD34+ /CD38+, CD34+ /CD38-, and CD34-/CD38- hematopoietic cells.
  • such cells maybe used to supplement populations of stem cells, e.g., cord blood cells, according to the methods of the invention.
  • the present invention further provides an isolated homogenous population of human placental stem cells that has the potential to differentiate into all cell types.
  • the population of human placental stem cells has the potential to differentiate into one cell type, hi yet another embodiment, the population of human placental stem cells has the potential to differentiate into several different cell types.
  • Such cells may be used to supplement populations of stem cells, e.g., cord blood cells, according to the methods of the invention.
  • the present invention also provides methods of mixing a population of stem cells with a population of embryonic-like stem cells, h one embodiment, the two populations are physically mixed, hi another aspect of this embodiment, the two populations are physically mixed and then treated with a growth factor, e.g., a cytokine and/or an interleukin, to induce cell differentiation.
  • a growth factor e.g., a cytokine and/or an interleukin
  • the stem cells and/or the embryonic-like stem cells are treated with a growth factor, e.g., a cytokine and/or an interleukin, to induce cell differentiation and then physically mixed.
  • the mixed populations are treated with a growth factor to induce differentiation into a variety of cell types.
  • the mixed populations are treated with a growth factor to induce differentiation into a particular cell type. In another embodiment, the mixed populations are treated with a growth factor to prevent or suppress differentiation into a particular cell type.
  • the culture conditions can be controlled, e.g., the mixed population of cells can be treated with a specific cocktail of cytokines or interleukins to direct or induce differentiation to a specific cell type.
  • the present invention provides pharmaceutical compositions that comprise populations of stem cells, e.g., cord blood cells, that have been supplemented with one or more populations of embryonic-like stem cells of the invention.
  • populations of stem cells e.g., cord blood cells
  • the invention also encompasses pharmaceutical compositions that comprise populations of stem cells, e.g., cord blood cells, supplemented with one or more populations of cells that have high concentrations (or larger populations) of homogenous hematopoietic stem cells including, but not limited to, CD34+ /CD38- cells; and CD34-/ CD38- cells.
  • populations of stem cells e.g., umbilical cord blood, supplemented with embryonic-like stem cells from the placenta have a multitude of uses, including therapeutic and diagnostic uses.
  • the supplemented populations of stem cells can be used for transplantation or to treat or prevent disease.
  • the supplemented populations of cells are used to renovate and repopulate tissues and organs, thereby replacing or repairing diseased tissues, organs or portions thereof,
  • the supplemented populations of stem cells can be used as a diagnostic to screen for genetic disorders or a predisposition for a particular disease or disorder.
  • the present invention also provides methods of treating a patient in need thereof by administration of a population of stem cells supplemented with embryonic-like stem cells.
  • the supplementation of the population of cord blood cells with embryonic-like stem cells occurs by mixing the stem cells and embryonic-like stem cells prior to administration of the supplemented population to the patient, hi another embodiment, the supplementation of the population of stem cells with embryonic-like stem cells occurs upon administration of the supplemented population to the patient, e.g., by simultaneous administration of the cord blood cells and the embryonic-like stem cells.
  • the supplementation of the population of stem cells with embryonic- like stem cells occurs after administration of the cord blood cells to the patient, e.g., by administering the embryonic-stem cells separately from, and before or after, administration of the stem cells.
  • a human placenta is recovered shortly after its expulsion after birth and, in certain embodiments, the cord blood in the placenta is recovered.
  • the placenta is subjected to a conventional cord blood recovery process.
  • cord blood recovery may be obtained commercially, e.g. , LifeBank Inc., Cedar Knolls, N.J., ViaCord, Cord Blood Registry and Cryocell.
  • the cord blood can be drained shortly after expulsion of the placenta.
  • the placenta is preheated according to the methods disclosed in co-pending application No. 10/076,180, filed February 13, 2002, which is incorporated herein by reference in its entirety.
  • the placenta after birth contains quiescent cells that can be activated if the placenta is properly processed after birth. For example, after expulsion from the womb, the placenta is exsanguinated as quickly as possible to prevent or minimize apoptosis. Subsequently, as soon as possible after exsanguination the placenta is perfused to remove blood, residual cells, proteins, factors and any other materials present in the organ. Materials debris may also be removed from the placenta. Perfusion is normally continued with an appropriate perfusate for at least two to more than twenty- four hours.
  • the placenta can therefore readily be used as a rich and abundant source of embryonic-like stem cells, which cells can be used for research, including drug discovery, treatment and prevention of diseases, in particular transplantation surgeries or therapies, and the generation of committed cells, tissues and organoids.
  • the human placental stem cells produced by the exsanguinated, perfused and/or cultured placenta are pluripotent stem cells that can readily be differentiated into any desired cell type.
  • stem or progenitor cells including, but not limited to embryonic-like stem cells, may be recovered from a placenta that is o exsanguinated, i. e. , completely drained of the cord blood remaining after birth and/or a conventional cord blood recovery procedure.
  • the methods for exsanguination of the placenta and removal of residual cells may be accomplished using any method known in the art, e.g., the methods disclosed in PCT publication WO 02/064755, published August 22, 2002, which is incorporated herein by 5 reference in its entirety.
  • the embryonic-like stem cells are observed to migrate into the exsanguinated and perfused 0 microcirculation of the placenta where, according to the methods of the invention, they are collected, preferably by washing into a collecting vessel by perfusion.
  • the placenta is cultured, and the cells propagated are monitored, sorted and/or characterized according to the methods described in PCT publication WO 02/064755, published August 22, 2002, which is incorporated herein by reference in its entirety. 5
  • embryonic-like stem cells migrate into the drained, empty microcirculation of the placenta where, according to the invention, they are collected, preferably by collecting the effluent perfusate in a collecting vessel.
  • cells cultured in the placenta are isolated from the effluent perfusate using techniques known by those skilled in the art, such as, for example, density gradient centrifugation, magnet cell separation, flow cytometry, or other cell separation or sorting methods well known in the art, and sorted.
  • the embryonic-like stem cells are collected from the placenta and, in certain embodiments, preserved, according to the methods described in PCT publication WO 02/064755, published August 22, 2002, which is incorporated herein by reference in its entirety.
  • Embryonic-like stem cells obtained in accordance with the methods of the invention may include pluripotent cells, i.e., cells that have complete differentiation versatility, that are self-renewing, and can remain dormant or quiescent within tissue.
  • the stem cells which may be obtained from the placenta include embryonic-like stem cells, multipotent cells, committed progenitor cells, and fibroblastoid cells.
  • the first collection of blood from the placenta is referred to as cord blood which contains predominantly CD34+ and CD38+ hematopoietic progenitor cells.
  • high concentrations of CD34+ and CD38- hematopoietic progenitor cells may be isolated from the placenta, along with high concentrations of CD34- and CD38+ hematopoietic progenitor cells. After about twenty-four hours of post-partum perfusion, high concentrations of CD34+ and CD38- hematopoietic progenitor cells may be isolated from the placenta, along with high concentrations of CD34- and CD38+ hematopoietic progenitor cells. After about twenty-
  • high concentrations of CD34- and CD38- cells can be isolated from the placenta along with the aforementioned cells.
  • the isolated perfused placenta of the invention provides a source of large quantities of stem cells enriched for CD34+ and CD38- stem cells and CD34- and CD38+ stem cells.
  • the isolated placenta which has been perfused for twenty-four hours or more provides a source of large quantities of stem cells
  • embryonic-like stem cells obtained by the methods of the invention are viable, quiescent, pluripotent stem cells that exist within a full-term human placenta and that can be recovered following successful birth and placental expulsion, resulting in the recovery of as many as one billion nucleated cells, which yield
  • the human placental stem cells provided by the placenta are surprisingly embryonic-like, for example, the presence of the following cell surface markers have been identified for these cells: SSEA3-, SSEA4-, OCT-4+ and ABC-p + .
  • the embryonic-like stem cells of the invention are characterized by the presence of OCT-4+ and ⁇ ABC-P+ cell surface markers.
  • the invention encompasses stem cells which have not been isolated or otherwise obtained from an embryonic source but which can be identified by the following markers: SSAE3-, SSAE4-, OCT-4+ and ABC-p+.
  • the human placental stem cells do not express MHC Class 2 antigens.
  • the stem cells isolated from the placenta are homogenous, and sterile. Further, the stem cells are readily obtained in a form suitable for administration to humans, i.e., they are of pharmaceutical grade.
  • Preferred embryonic-like stem cells obtained by the methods of the invention may be identified by the presence of the following cell surface markers: OCT-4+ and ABC-pt. Further, the invention encompasses embryonic stem cells having the following markers: CD 10+, CD38-, CD29+, CD34-, CD44+, CD45-, CD54+, CD90+, SH2+, SH3+, SH4+, SSEA3-, SSEA4-, OCT-4+, and ABC- ⁇ +.
  • Such cell surface markers are routinely determined according to methods well known in the art, e.g. by flow cytometry, followed by washing and staining with an anti-cell surface marker antibody.
  • cells may be washed in PBS and then double-stained with anti-CD34 phycoerythrin and anti-CD38 fluorescein isothiocyanate (Becton Dickinson, Mountain View, CA).
  • cells cultured in the placenta bioreactor are identified and characterized by a colony forming unit assay, which is commonly known in the art, such as Mesen CultTM medium (stem cell Technologies, Inc., Vancouver British Columbia)
  • embryonic-like stem cells obtained by the methods of the invention maybe induced to differentiate along specific cell lineages, including adipogenic, chondrogenic, osteogenic, hematopoietic, myogenic, vasogenic, neurogenic, and hepatogenic.
  • embryonic-like stem cells obtained according to the methods of the invention are induced to differentiate for use in transplantation and ex vivo treatment protocols, hi certain embodiments, embryonic-like stem cells obtained by the methods of the invention are induced to differentiate into a particular cell type and genetically engineered to provide a therapeutic gene product.
  • embryonic-like stem cells obtained by the methods of the invention are incubated with a compound in vitro that induces it to differentiate, followed by direct transplantation of the differentiated cells to a subject.
  • the invention encompasses methods of differentiating the human placental stem cells using standard culturing media.
  • the invention encompasses hematopoietic cells, neuron cells, fibroblast cells, strand cells, mesenchymal cells and hepatic cells.
  • Embryonic-like stem cells may also be further cultured after collection from the placenta using methods well known in the art, for example, by culturing on feeder cells, such as irradiated fibroblasts, obtained from the same placenta as the embryonic-like stem cells or from other human or nonhuman sources, or in conditioned media obtained from cultures of such feeder cells, in order to obtain continued long-term cultures of embryonic- like stem cells.
  • the embryonic-like stem cells may also be expanded, either within the placenta before collection from the placental bioreactor or in vitro after recovery from the placenta, hi certain embodiments, the embryonic-like stem cells to be expanded are exposed to, or cultured in the presence of, an agent that suppresses cellular differentiation.
  • Such agents include, but are not limited to, human Delta- 1 and human Serrate-1 polypeptides (see, Sakano et al, U.S. Patent No. 6,337,387 entitled “Differentiation-suppressive polypeptide", issued January 8, 2002), leukemia inhibitory factor (LJF) and stem cell factor.
  • LJF leukemia inhibitory factor
  • stem cell factor stem cell factor
  • the embryonic-like stem cells may be assessed for viability, proliferation potential, and longevity using standard techniques known in the art, such as trypan blue exclusion assay, fluorescein diacetate uptake assay, propidium iodide uptake assay (to assess viability); and thymidine uptake assay, MTT cell proliferation assay (to assess proliferation). Longevity may be determined by methods well known in the art, such as by determining the maximum number of population doubling in an extended culture.
  • the differentiation of stem cells or progenitor cells that are cultivated in the exsanguinated, perfused and/or cultured placenta is modulated using an agent or pharmaceutical compositions comprising a dose and/or doses effective upon single or multiple administration, to exert an effect sufficient to inhibit, modulate and/or regulate the differentiation of a cell collected from the placenta.
  • Agents that can induce stem or progenitor cell differentiation include, but are not limited to, Ca 2+ , EGF, ⁇ -FGF, ⁇ -FGF, PDGF, keratinocyte growth factor (KGF), TGF- ⁇ , cytokines (e.g., LL-l ⁇ , TL-l ⁇ , LFN- ⁇ , TFN), retinoic acid, transferrin, hormones (e.g., androgen, estrogen, insulin, prolactin, triiodothyronine, hydrocortisone, dexamethasone), sodium butyrate, TPA, DMSO, NMF, DMF, matrix elements (e.g., collagen, laminin, heparan sulfate, MatrigelTM), or combinations thereof.
  • KGF keratinocyte growth factor
  • TGF- ⁇ cytokines
  • transferrin e.g., hormones (e.g., androgen, estrogen, insulin, prolactin, triiod
  • Agents that suppress cellular differentiation include, but are not limited to, human Delta- 1 and human Serrate-1 polypeptides (see, Sakano et al, U.S. Patent No. 6,337,387 entitled “Differentiation-suppressive polypeptide", issued January 8, 2002), leukemia inhibitory factor (LIF), and stem cell factor.
  • human Delta- 1 and human Serrate-1 polypeptides see, Sakano et al, U.S. Patent No. 6,337,387 entitled “Differentiation-suppressive polypeptide”, issued January 8, 2002
  • LIF leukemia inhibitory factor
  • stem cell factor stem cell factor
  • the agent used to modulate differentiation can be introduced into the placental bioreactor to induce differentiation of the cells being cultured in the placenta.
  • the agent can be used to modulate differentiation in vitro after the cells have been collected or removed from the placenta.
  • Determination that a stem cell has differentiated into a particular cell type may be accomplished by methods well-known in the art, e.g., measuring changes in morphology and cell surface markers using techniques such as flow cytometry or immunocytochemistry (e.g., staining cells with tissue-specific or cell-marker specific antibodies), by examination of the morphology of cells using light or confocal microscopy, or by measuring changes in gene expression using techniques well known in the art, such as PCR and gene-expression profiling.
  • the present invention relates to populations of stem cells are mixed with embryonic- like stem cells.
  • stems cells that may be mixed with embryonic-like stem cells include, but are not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow.
  • the embryonic-like stem cells of the invention are mixed with umbilical cord blood.
  • the present invention provides an isolated homogenous population of human placental stem cells (embryonic-like stem cells) which has the potential to differentiate into all cell types. Such cells may be used to supplement populations of stem cells, e.g., cord blood cells, according to the methods of the invention.
  • stem cells e.g., cord blood cells
  • the invention also provides populations of cord blood cells that have been supplemented (i.e., mixed, combined or augmented) with populations of embryonic-like stem cells that originate from a placenta.
  • the supplemented populations are very versatile, in that they contain populations of cells that are pluripotent or multipotent stem cells, e.g., cells displaying a CD34+ /CD38+, CD34+ /CD38- or CD34-/CD38- phenotype.
  • the supplemented populations of stem cells of the invention contain embryonic-like stem cells and other stem or progenitor cells at a ratio of 100,000,000:1, 50,000,000:1, 20,000,000:1, 10,000,000:1, 5,000,000:1, 2,000,000:1, 1,000,000:1, 500,000:1, 200,000:1, 100,000:1, 50,000:1, 20,000:1, 10,000:1, 5,000:1, 2,000:1, 1,000:1, 500:1, 200:1, 100:1, 50:1, 20:1, 10:1, 5:1, 2:1, 1:1; 1:2; 1:5; 1:10; 1:100; 1:200; 1:500; 1:1,000; 1:2,000; 1:5,000; 1:10,000; 1:20,000; 1:50,000; 1:100,000; 1:500,000; 1:1,000,000; 1:2,000,000; 1:5,000,000; 1:10,000,000; 1:20,000,000; 1:50,000,000; or 1:100,000,000, comparing numbers of total nucleated cells in each population.
  • the invention provides methods for supplementing, mixing, combining or augmenting stem cells, e.g., umbilical cord blood, with a composition of the invention, e.g., a population of pure embryonic-like placental stem cells or a population of cells enriched for embryonic-like placental stem cells.
  • a composition of the invention e.g., a population of pure embryonic-like placental stem cells or a population of cells enriched for embryonic-like placental stem cells.
  • an aliquot (or population) of embryonic-like placental stem cells is added to an aliquot of umbilical cord blood, before delivery to a patient in need thereof.
  • the present invention also provides methods of supplementing a population of cord blood cells with a population of embryonic-like stem cells.
  • the two populations are physically mixed.
  • the two populations are physically mixed and then treated with a growth factor, e.g., a cytokine and/or an interleukin, to induce cell differentiation.
  • the cord blood cells and/or the embryonic-like stem cells are treated with a growth factor, e.g., a cytokine and/or an interleukin, to induce cell differentiation and then physically mixed.
  • the present invention also provides methods of treating a patient in need thereof by administration of a population of cord blood cells supplemented with embryonic-like stem cells.
  • the supplementing of the population of cord blood cells with embryonic-like stem cells occurs by mixing the cord blood cells and embryonic-like stem cells prior to administration of the supplemented population to the patient.
  • supplementing the population of cord blood cells with embryonic-like stem cells occurs upon administration of the supplemented population to the patient, e.g., by simultaneous administration of the cord blood cells and the embryonic-like stem cells.
  • supplementing of the population of cord blood cells with embryonic- like stem cells occurs after administration of the cord blood cells to the patient, e.g., by administering the embryonic-stem cells separately from, and before or after, administration of the cord blood cells.
  • the invention provides methods for supplementing cord blood cells with embryonic-like stem cells, wherein the mixture is contained within one bag.
  • the invention provides methods for supplementing cord blood cells with embryonic-like stem cells, wherein the cord blood cells and the embryonic-like stem cells are each contained in a separate bags.
  • Such a "two bag" composition may be mixed prior to or at the time of administration to a patient in need thereof.
  • an aliquot (or population) of embryonic-like placental stem cells are conditioned before being added to, and mixed into, an aliquot of umbilical cord blood before delivery to a patient in need thereof.
  • a population of embryonic-like placental stem cells is induced to differentiate into a particular cell lineage, e.g., a hematopoietic, neuronal, adipogenic, chondrogenic, osteogenic, hepatogenic, pancreatic, or myogenic lineage, as disclosed above in Section 4.3, by exposure to, e.g., cytokines (e.g., IL-l ⁇ , IL-l ⁇ , IFN- ⁇ , TFN), retinoic acid, transferrin, hormones (e.g., androgen, estrogen, insulin, prolactin, triiodothyronine, hydrocortisone, dexamethasone), sodium butyrate, TPA, DMSO, NMF, DMF, matrix elements (e.g., collagen, laminin, heparan sulfate, MatrigelTM), or combinations thereof, before being added to, and mixed into, an aliquot of umbilical
  • cytokines e.
  • a population of embryonic-like placental stem cells is conditioned by being exposed to an agent that suppresses differentiation, e.g. , human Delta- 1 and human Serrate-1 polypeptides, or combinations thereof, before being added to, and mixed into, an aliquot of umbilical cord blood.
  • an agent that suppresses differentiation e.g. , human Delta- 1 and human Serrate-1 polypeptides, or combinations thereof.
  • an aliquot (or population) of non-conditioned embryonic- like placental stem cells and an aliquot of umbilical cord blood are mixed, and the mixed population of cells is conditioned before being delivery to a patient in need thereof, hi specific embodiments, the mixed population of embryonic-like placental stem cells and umbilical cord blood cells are conditioned with an agent that induces or suppresses cell differentiation as disclosed above.
  • a population of embryonic-like stem cells of the invention is added to, or mixed into, a population of umbilical cord blood cells prior to administration to a patient in need thereof, hi another specific embodiment, a population of embryonic- like stem cells of the invention is added to, or mixed into, a population of umbilical cord blood cells during, or simultaneous with, administration to a patient in need thereof.
  • a population of embryonic-like stem cells of the invention and a population of umbilical cord blood cells are administered sequentially to a patient in need thereof.
  • the population of embryonic-like stem cells is administered first and the population of umbilical cord blood cells is administered second.
  • the population of umbilical cord blood cells is administered first and the population of embryonic-like placental stem cells is administered second.
  • the populations of cord blood cells spiked with embryonic-like stem cells may be cultured, induced to propagate, and/or induced to differentiate under a variety of conditions, including but not limited to treating the spiked populations by introduction of nutrients, hormones, vitamins, growth factors, or any combination thereof, into the culture medium. Serum and other growth factors may be added to the culture medium. Growth factors are usually proteins and include, but are not limited to: cytokines, lymphokines, interferons, colony stimulating factors (CSF's), interferons, chemokines, and interleukins.
  • growth factors include recombinant human hematopoietic growth factors including ligands, stem cell factors, thrombopoeitin (Tpo), granulocyte colony-stimulating factor (G-CSF), leukemia inhibitory factor, basic fibroblast growth factor, placenta derived growth factor and epidermal growth factor.
  • the supplemented populations are treated with a growth factor to induce differentiation into a variety of cell types, hi another embodiment, the spiked populations are treated with a growth factor to induce differentiation into a particular cell type. In another embodiment, the supplemented populations are treated with a growth factor to prevent or suppress differentiation into a particular cell type.
  • the methods of supplementing a population of cord blood comprise (a) induction of differentiation of embryonic-like stem cells, (b) mixing the embryonic-like stem cells with a population of cord blood cells and (c) administration of the mixture to a patient in need thereof.
  • the methods of supplementing a population of cord blood comprise (a) mixing the embryonic-like stem cells with a population of cord blood cells; (b) induction of differentiation of the mixture of the spiked population of cord blood cells and embryonic-like stem cells and (c) administration of the mixture to a patient in need thereof.
  • the methods of supplementing a population of cord blood comprise (a) administration of a mixture of cord blood cells supplemented with embryonic-like stem cells to a patient in need thereof and (b) induction of differentiation of the mixture and (c) administration of the mixture to a patient in need thereof.
  • stem or progenitor cells are induced to differentiate into a particular cell type, by exposure to a growth factor, according to methods well known in the art.
  • the growth factor is: GM-CSF, LL-4, Flt3L, CD40L, IFN- alpha, TNF-alpha, IFN-gamma, IL-2, IL-6, retinoic acid, basic fibroblast growth factor, TGF-beta-1, TGF-beta-3, hepatocyte growth factor, epidermal growth factor, cardiotropin-1, angiotensinogen, angiotensin I (Al), angiotensin JJ (AH), ATI AT 2 type 2 receptor agonists, or analogs or fragments thereof.
  • stem or progenitor cells are induced to differentiate into neurons, according to methods well known in the art, e.g., by exposure to ⁇ - mercaptoethanol or to DMSO/butylated hydroxyanisole, according to the methods disclosed in Section 5.4.1.
  • stem or progenitor cells are induced to differentiate into adipocytes, according to methods well known in the art, e.g., by exposure to dexamethasone, indomethacin, insulin and IBMX, according to the methods disclosed in Section 5.4.2.
  • stem or progenitor cells are induced to differentiate into chondrocytes, according to methods well known in the art, e.g., by exposure to TGF-.beta-3, according to the methods disclosed in Section 5.4.3.
  • stem or progenitor cells are induced to differentiate into osteocytes, according to methods well known in the art, e.g., by exposure to dexamethasone, ascorbic acid-2 -phosphate and beta-glycerophosphate, according to the methods disclosed in Section 5.4.4.
  • stem or progenitor cells are induced to differentiate into hepatocytes, according to methods well known in the art, e.g., by exposure to LL-6 +/- LL-15, according to the methods disclosed in Section 5.4.5.
  • stem or progenitor cells are induced to differentiate into pancreatic cells, according to methods well known in the art, e.g., by exposure to basic fibroblast growth factor, and transforming growth factor beta- 1, according to the methods disclosed in Section 5.4.6.
  • stem or progenitor cells are induced to differentiate into cardiac cells, according to methods well known in the art, e.g., by exposure to retinoic acid , basic fibroblast growth factor, TGF-beta-1 and epidermal growth factor, by exposure to cardiotropin-1 or by exposure to human myocardium extract, according to the methods disclosed in Section 5.4.7.
  • the embryonic-like stem cells are stimulated to produce bioactive molecules, such as immunoglobulins, hormones, enzymes.
  • the embryonic-like stem cells are stimulated to proliferate, for example, by administration of erythropoietin, cytokines, lymphokines, interferons, colony stimulating factors (CSF's), interferons, chemokines, interleukins, recombinant human hematopoietic growth factors including ligands, stem cell factors, thrombopoeitin (Tpo), interleukins, and granulocyte colony-stimulating factor (G-CSF) or other growth factors.
  • CSF's colony stimulating factors
  • chemokines chemokines
  • interleukins recombinant human hematopoietic growth factors including ligands, stem cell factors, thrombopoeitin (Tpo), interleukins, and granulocyte colony-stimulating factor (G-CSF) or other growth factors.
  • G-CSF granulocyte colony-stimulating factor
  • the embryonic-like stem cells are genetically engineered either prior to, or after collection from, the placenta, using, for example, a viral vector such as an adenoviral or retroviral vector, or by using mechanical means such as liposomal or chemical mediated uptake of the DNA.
  • a viral vector such as an adenoviral or retroviral vector
  • mechanical means such as liposomal or chemical mediated uptake of the DNA.
  • a vector containing a transgene can be introduced into a cell of interest by methods well known in the art, e.g., transfection, transformation, transduction, electroporation, infection, microinjection, cell fusion, DEAE dextran, calcium phosphate precipitation, liposomes, LIPOFECTINTM, lysosome fusion, synthetic cationic lipids, use of a gene gun or a DNA vector transporter, such that the transgene is transmitted to daughter cells, e.g., the daughter embryonic-like stem cells or progenitor cells produced by the division of an embryonic-like stem cell.
  • daughter cells e.g., the daughter embryonic-like stem cells or progenitor cells produced by the division of an embryonic-like stem cell.
  • the transgene is introduced using any technique, so long as it is not destructive to the cell's nuclear membrane or other existing cellular or genetic structures, hi certain embodiments, the transgene is inserted into the nucleic genetic material by microinjection. Microinjection of cells and cellular structures is commonly known and practiced in the art.
  • a gene that encodes a selectable marker (e.g., for resistance to antibiotics) is generally introduced into the host embryonic-like stem cell along with the gene sequence of interest.
  • selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate.
  • Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g. , cells that have incorporated the selectable marker gene will survive, while the other cells die).
  • drug selection e.g. , cells that have incorporated the selectable marker gene will survive, while the other cells die.
  • Such methods are particularly useful in methods involving homologous recombination in mammalian cells (e.g., in embryonic-like stem cells) prior to introduction or transplantation of the recombinant cells into a subject or patient.
  • a number of selection systems may be used to select transformed host embryonic- like cells.
  • the vector may contain certain detectable or selectable markers.
  • Other methods of selection include but are not limited to selecting for another marker such as: the herpes simplex virus thymidine kinase (Wigler et al, 1977, Cell 11: 223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska and Szybalski, 1962, Proc. Natl. Acad. Sci.
  • adenine phosphoribosyltransferase genes can be employed in tk-, hgprt- or aprt- cells, respectively.
  • antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al, 1980, Proc. Natl. Acad. Sci. USA 77: 3567; O'Hare et al, 1981, Proc. Natl. Acad. Sci. USA 78: 1527); gpt, which confers resistance to mycophenolic acid (Mulligan and Berg, 1981, Proc.
  • the transgene may integrate into the genome of the cell of interest, preferably by random integration, hi other embodiments the transgene may integrate by a directed method, e.g., by directed homologous recombination (i.e., "knock-in” or "knock-out” of a gene of interest in the genome of cell of interest), Chappel, U.S. Patent No. 5,272,071; and PCT publication No. WO 91/06667, published May 16, 1991; U.S. Patent 5,464,764; Capecchi et al, issued November 7, 1995; U.S. Patent 5,627,059, Capecchi et al. issued, May 6, 1997; U.S. Patent 5,487,992, Capecchi et al, issued January 30, 1996).
  • directed homologous recombination i.e., "knock-in” or "knock-out” of a gene of interest in the genome of cell of interest
  • Chappel U.S. Patent No. 5,272,07
  • the construct will comprise at least a portion of a gene of interest with a desired genetic modification, and will include regions of homology to the target locus, i.e., the endogenous copy of the targeted gene in the host's genome.
  • DNA constructs for random integration in contrast to those used for homologous recombination, need not include regions of homology to mediate recombination. Markers can be included in the targeting construct or random construct for performing positive and negative selection for insertion of the transgene.
  • a homologous recombination vector is prepared in which a gene of interest is flanked at its 5' and 3' ends by gene sequences that are endogenous to the genome of the targeted cell, to allow for homologous recombination to occur between the gene of interest carried by the vector and the endogenous gene in the genome of the targeted cell.
  • the additional flanking nucleic acid sequences are of sufficient length for successful homologous recombination with the endogenous gene in the genome of the targeted cell.
  • flanking DNA typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector.
  • Methods for constructing homologous recombination vectors and homologous recombinant animals from recombinant stem cells are commonly known in the art (see, e.g., Thomas and Capecchi, 1987, Cell 51: 503; Bradley, 1991, Curr. Opin. Bio/Technol. 2: 823- 29; and PCT Publication Nos. WO 90/11354, WO 91/01140, and WO 93/04169.
  • the genome of an exogenous cell cultured in the placenta according to the methods of the invention is a target of gene targeting via homologous recombination or via random integration.
  • the methods of Bonadio et al. are used to introduce nucleic acids into a cell of interest, such as a stem cell, progenitor cell or exogenous cell cultured in the placenta, e.g., bone progenitor cells.
  • SUPPLEMENTED POPULATIONS OF STEM CELLS Embryonic-like stem cells may be obtained from perfused placentas according to the methods described in copending United States Application No. 01/076,180, filed February 13, 2002.
  • the placental stem cell may be induced to differentiate into a particular cell type, either ex vivo or in vivo.
  • pluripotent embryonic-like stem cells may be injected into a damaged organ, and for organ neogenesis and repair of injury in vivo.
  • Such injury may be due to such conditions and disorders including, but not limited to, myocardial infarction, seizure disorder, multiple sclerosis, stroke, hypotension, cardiac arrest, ischemia, inflammation, age-related loss of cognitive function, radiation damage, cerebral palsy, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Leigh disease, ADDS dementia, memory loss, amyotrophic lateral sclerosis, ischemic renal disease, brain or spinal cord trauma, heart-lung bypass, glaucoma, retinal ischemia, or retinal trauma.
  • the embryonic-like stem cells isolated from the placenta, alone or in combination with stem or progenitor cell populations may be used, in specific embodiments, in autologous or heterologous enzyme replacement therapy to treat specific diseases or conditions, including, but not limited to lysosomal storage diseases, such as Tay-Sachs, Niemann-Pick, Fabry's, Gaucher's, Hunter's, and Hurler's syndromes, as well as other gangliosidoses, mucopolysaccharidoses, and glycogenoses.
  • lysosomal storage diseases such as Tay-Sachs, Niemann-Pick, Fabry's, Gaucher's, Hunter's, and Hurler's syndromes, as well as other gangliosidoses, mucopolysaccharidoses, and glycogenoses.
  • the embryonic-like stem cells may be used as autologous or heterologous transgene carriers in gene therapy to correct inborn errors of metabolism, adrenoleukodystrophy, cystic fibrosis, glycogen storage disease, hypothyroidism, sickle cell anemia, Pearson syndrome, Pompe's disease, phenylketonuria (PKU), porphyrias, maple syrup urine disease, homocystinuria, mucoplysaccharide nosis, chronic granulomatous disease and tyrosinemia and Tay-Sachs disease or to treat cancer, tumors or other pathological conditions.
  • adrenoleukodystrophy cystic fibrosis
  • glycogen storage disease hypothyroidism
  • sickle cell anemia Pearson syndrome
  • Pompe's disease phenylketonuria
  • porphyrias maple syrup urine disease
  • homocystinuria mucoplysaccharide nosis
  • the cell compositions may be used in autologous or heterologous tissue regeneration or replacement therapies or protocols, including, but not limited to treatment of corneal epithelial defects, cartilage repair, facial dermabrasion, mucosal membranes, tympanic membranes, intestinal linings, neurological structures (e.g., retina, auditory neurons in basilar membrane, olfactory neurons in olfactory epithelium), bum and wound repair for traumatic injuries of the skin, or for reconstruction of other damaged or diseased organs or tissues.
  • corneal epithelial defects e.g., cartilage repair, facial dermabrasion, mucosal membranes, tympanic membranes, intestinal linings, neurological structures (e.g., retina, auditory neurons in basilar membrane, olfactory neurons in olfactory epithelium), bum and wound repair for traumatic injuries of the skin, or for reconstruction of other damaged or diseased organs or tissues.
  • cartilage repair e.g., corneal epi
  • the large numbers of embryonic-like stem cells and/or progenitor obtained using the methods of the invention would, in certain embodiments, reduce the need for large bone marrow donations.
  • Approximately 1 x 10 8 to 2 x 10 8 bone marrow mononuclear cells per kilogram of patient weight must be infused for engraftment in a bone marrow transplantation (i.e., about 70 ml of marrow for a 70 kg donor).
  • a small bone marrow donation e.g., 7-10 ml
  • stem cells and progenitor cells normally circulate in the blood stream.
  • exogenous stem cells or exogenous progenitor cells are collected by apheresis, a procedure in which blood is withdrawn, one or more components are selectively removed, and the remainder of the blood is reinfused into the donor.
  • the exogenous cells recovered by apheresis are expanded by propagation in a placental bioreactor, thus eliminating the need for bone marrow donation entirely.
  • the embryonic-like stem cells, progenitor cells, foreign cells, or engineered cells obtained from a placenta according to the methods of the invention, alone or in combination with other stem cell or progenitor cell populations, can be used in the manufacture of a tissue or organ in vivo.
  • the methods of the invention encompass using cells obtained from the placenta, e.g., embryonic-like stem cells, progenitor cells, or foreign stem or progenitor cells, to seed a matrix and to be cultured under the appropriate conditions to allow the cells to differentiate and populate the matrix.
  • the tissues and organs obtained by the methods of the invention may be used for a variety of purposes, including research and therapeutic purposes.
  • the embryonic-like stem cells and the supplemented populations of stem cells of the invention can also be used for a wide variety of prophylactic or therapeutic protocols in which a tissue or organ of the body is augmented, repaired or replaced by the engraftment, transplantation or infusion of a desired cell population, such as a stem cell or progenitor cell population.
  • the embryonic-like stem cells and the supplemented populations of stem cells of the invention can be used to replace or augment existing tissues, to introduce new or altered tissues, or to join together biological tissues or structures.
  • the embryonic-like stem and supplemented stem cell populations of the invention can also be substituted for embryonic stem cells in therapeutic protocols described herein in which embryonic stem cells would be typically be used.
  • embryonic-like stem cells and supplemented stem cell populations may be used as autologous and allogenic, including matched and mismatched HLA type hematopoietic transplants.
  • embryonic-like stem cells as allogenic hematopoietic transplants it may be necessary to treat the host to reduce immunological rejection of the donor cells, such as those described in U.S. Patent No. 5,800,539, issued September 1, 1998; and U.S. Patent No. 5,806,529, issued September 15, 1998, both of which are incorporated herein by reference.
  • embryonic-like stem cells and supplemented stem cell populations of the invention can be used in therapeutic transplantation protocols, e.g., to augment or replace stem or progenitor cells of the liver, pancreas, kidney, lung, nervous system, muscular system, bone, bone marrow, thymus, spleen, mucosal tissue, gonads, or hair.
  • Embryonic-like stem cells and supplemented stem cell populations may be used instead of specific classes of progenitor cells (e.g., chondrocytes, hepatocytes, hematopoietic cells, pancreatic parenchymal cells, neuroblasts, muscle progenitor cells, etc.) in therapeutic or research protocols in which progenitor cells would typically be used.
  • Embryonic-like stem cells and supplemented stem cell populations of the invention can be used for augmentation, repair or replacement of cartilage, tendon, or ligaments.
  • prostheses e.g., hip prostheses
  • joints e.g., knee
  • Cartilage tissue constructs can also be employed in major reconstructive surgery for different types of joints (for protocols, see e.g., Resnick, D., and Niwayama, G., eds., 1988, Diagnosis of Bone and Joint Disorders, 2d ed., W. B. Saunders Co.).
  • the embryonic-like stem cells and supplemented stem cell populations of the invention can be used to repair damage of tissues and organs resulting from trauma, metabolic disorders, or disease.
  • a patient can be administered embryonic-like stem cells, alone or combined with other stem or progenitor cell populations, to regenerate or restore tissues or organs which have been damaged as a consequence of disease, e.g., enhance immune system following chemotherapy or radiation, repair heart tissue following myocardial infarction.
  • the embryonic-like stem cells and supplemented stem cell populations of the invention can be used to augment or replace bone marrow cells in bone marrow transplantation.
  • Human autologous and allogenic bone marrow transplantation are currently used as therapies for diseases such as leukemia, lymphoma and other life-threatening disorders. The drawback of these procedures, however, is that a large amount of donor bone marrow must be removed to insure that there is enough cells for engraftment.
  • the embryonic-like stem cells and supplemented stem cell populations of the invention can provide stem cells and progenitor cells that would reduce the need for large bone marrow donation. It would also be, according to the methods of the invention, to obtain a small marrow donation and then expand the number of stem cells and progenitor cells culturing and expanding in the placenta before infusion or transplantation into a recipient.
  • the embryonic-like stem cells and supplemented stem cell populations of the invention may be used, in specific embodiments, in autologous or heterologous enzyme replacement therapy to treat specific diseases or conditions, including, but not limited to lysosomal storage diseases, such as Tay-Sachs, Niemann-Pick, Fabry's, Gaucher's,
  • the cells may be used as autologous or heterologous transgene carriers in gene therapy to correct inborn errors of metabolism such as adrenoleukodystrophy, cystic fibrosis, glycogen storage disease, hypothyroidism, sickle cell anemia, Pearson syndrome, Pompe's disease, phenylketonuria (PKU), and Tay-Sachs disease, porphyrias, maple syrup urine disease, homocystinuria, mucopolypsacchari.de nosis, chronic granulomatous disease, and tyrosinemia. or to treat cancer, tumors or other pathological or neoplastic conditions.
  • the cells may be used in autologous or heterologous tissue regeneration or replacement therapies or protocols, including, but not limited to treatment of corneal epithelial defects, cartilage repair, facial dermabrasion, mucosal membranes, tympanic membranes, intestinal linings, neurological structures (e.g., retina, auditory neurons in basilar membrane, olfactory neurons in olfactory epithelium), burn and wound repair for traumatic injuries of the skin, scalp (hair) transplantation, or for reconstruction of other damaged or diseased organs or tissues.
  • therapies or protocols including, but not limited to treatment of corneal epithelial defects, cartilage repair, facial dermabrasion, mucosal membranes, tympanic membranes, intestinal linings, neurological structures (e.g., retina, auditory neurons in basilar membrane, olfactory neurons in olfactory epithelium), burn and wound repair for traumatic injuries of the skin, scalp (hair) transplantation, or for reconstruction of other damaged or diseased organs or
  • the large numbers of embryonic-like stem cells and/or progenitor obtained using the methods of the invention would, in certain embodiments, reduce the need for large bone marrow donations.
  • Approximately 1 x 10 8 to 2 x 10 8 bone marrow mononuclear cells per kilogram of patient weight must be infused for engraftment in a bone marrow transplantation (i.e., about 70 ml of marrow for a 70 kg donor).
  • 70 ml requires an intensive donation and significant loss of blood in the donation process.
  • cells from a small bone marrow donation e.g., 7-10 ml
  • the embryonic-like stem cells and supplemented stem cell populations of the invention can be used in a supplemental treatment in addition to chemotherapy.
  • Most chemotherapy agents used to target and destroy cancer cells act by killing all proliferating cells, i.e., cells going through cell division. Since bone marrow is one of the most actively proliferating tissues in the body, hematopoietic stem cells are frequently damaged or destroyed by chemotherapy agents and in consequence, blood cell production is diminishes or ceases.
  • Chemotherapy must be terminated at intervals to allow the patient's hematopoietic system to replenish the blood cell supply before resuming chemotherapy.
  • the human placental stem cells can be used to treat or prevent genetic diseases such as chronic granulomatous disease.
  • the present invention encompasses pharmaceutical compositions which comprise the embryonic-like stem cells and supplemented stem cell populations of the invention.
  • the present invention encompasses pharmaceutical compositions comprising a dose and/or doses effective upon single or multiple administration, prior to or following transplantation of conditioned or unconditioned human progenitor stem cells, that are able to exert an effect sufficient to inhibit, modulate and/or regulate the differentiation of human pluripotent and multipotent progenitor stem cells of placental origin into one or more cell lineages, for example, mesodermal, adipose, chondrocytic, osteocytic, myocytic, vascular, neural, o endothelial, hepatic, kidney, pancreatic, and/or hematopoietic lineage cells.
  • the embryonic-like stem cells and supplemented stem cell populations of the invention maybe formulated as an injectable (e.g., PCT WO 96/39101, incorporated herein by reference in its entirety).
  • the cells and tissues of the present invention may be formulated using 5 polymerizable or cross linking hydrogels as described in U.S. Patent Nos. 5,709,854; 5,516,532; 5,654,381; each of which is incorporated by reference in their entirety.
  • the embryonic-like stem cells may be administered as obtained from the placenta, or may be spiked into umbilical cord blood and administered as a mixed cell composition, or may be placed into any physiologically-acceptable buffer or fluid for administration to an individual.
  • the invention also encompasses pharmaceutical compositions that have high concentrations (or larger populations) of homogenous embryonic-like stem cells, wherein one or more of these cell populations can be used with, or as a mixture with, other stem or progenitor cells, for use in transplantation and other uses.
  • stem or progenitor cells may include but are not limited to: adipogenic, chondrogenic, osteogenic, hematopoietic, myogenic, vasogenic, neurogenic, and hepatogenic stem cells; mesenchymal stem cells, stromal cells, endothelial cells, hepatocytes, keratinocytes, and stem or progenitor cells for a particular cell type, tissue or organ, including but not limited to neurons, myelin, muscle, blood, bone marrow, skin, heart, connective tissue, lung, kidney, liver, and pancreas (e.g., pancreatic islet cells).
  • adipogenic, chondrogenic, osteogenic, hematopoietic, myogenic, vasogenic, neurogenic, and hepatogenic stem cells mesenchymal stem cells, stromal cells, endothelial cells, hepatocytes, keratinocytes, and stem or progenitor cells for a particular cell type, tissue or organ, including but not
  • the invention provides pharmaceutical compositions that have high concentrations (or larger populations) of homogenous hematopoietic stem cells including but not limited to CD34+ /CD38- cells; and CD34-/ CD38- cells.
  • high concentrations or larger populations
  • the pharmaceutical composition comprises embryonic-like placental stem cells of the invention and cord blood hematopoietic cells i.e., CD34+/CD38+ hematopoietic cells.
  • One or more of these cell populations can be used with or as a mixture with cord blood hematopoietic cells i.e., CD34+/CD38+ hematopoietic cells for transplantation and other uses.
  • the invention provides heterogeneous population of nucleated cells that comprises embryonic-like placental stem cells.
  • a heterogeneous population of nucleated cells (rather than a pure population CD34+ cells embryonic-like placental stem cells) is preferred.
  • the invention provides a mixed population of cells (e.g. , cord blood cells and embryonic-like placental stem cells). The population of mixed cells may be frozen or unfrozen. Such a mixed population may be stored and/or used in one container, e.g., one bag or one syringe.
  • the invention provides two or more separate or distinct populations of different cell types (e.g., cord blood cells and embryonic-like placental stem cells).
  • Each separate population may be stored and/or used in a separate container, e.g., one bag (e.g., blood storage bag from Baxter, Becton-Dickinson, Medcep, National Hospital Products or Terumo) or one syringe, which contains a single type of cell or cell population.
  • the invention provides separate containers of different cell types to be mixed before administration. Such cells may be unfrozen or frozen.
  • cord blood cells are contained in one bag and embryonic- like placental stem cells are contained in a second bag.
  • the invention provides embryonic-like placental stem cells that are "conditioned" before freezing.
  • a population of cells including, but not limited to, embryonic-like placental stem cells may be conditioned by the removal of red blood cells and/or granulocytes according to standard methods, so that a population of nucleated cells remains that is enriched for embryonic-like placental stem cells.
  • Such an enriched population of embryonic-like placental stem cells may be used unfrozen, or frozen for later use. If the population of cells is to be frozen, a standard cryopreservative (e.g., DMSO, glycerol, EpilifeTM Cell Freezing Medium (Cascade Biologies)) is added to the enriched population of cells before it is frozen.
  • a population of cells including, but not limited to, embryonic-like placental stem cells may be conditioned by the removal of red blood cells and/or granulocytes after it has been frozen and thawed.
  • agents that induce cell differentiation may be used to condition a population of embryonic-like stem cells.
  • an agent that induces differentiation can be added to a population of cells within a container, including, but not limited to, Ca 2+ , EGF, ⁇ -FGF, ⁇ -FGF, PDGF, keratinocyte growth factor (KGF), TGF- ⁇ , cytokines (e.g., IL-l ⁇ , LL-l ⁇ , IFN- ⁇ , TFN), retinoic acid, transferrin, hormones (e.g., androgen, estrogen, insulin, prolactin, triiodothyronine, hydrocortisone, dexamethasone), sodium butyrate, TPA, DMSO, NMF, DMF, matrix elements (e.g., collagen, laminin, heparan sulfate, MatrigelTM), or combinations thereof.
  • Ca 2+ e.g., EGF, ⁇ -FGF, ⁇ -FGF, PDGF, keratinocyte growth factor (KGF), TGF- ⁇ , cytokines (
  • agents that suppress cellular differentiation can be added to a population of embryonic-like stem cells.
  • an agent that suppresses differentiation can be added to a population of cells within a container, including, but not limited to, human Delta-1 and human Serrate-1 polypeptides (see, Sakano et al, U.S. Patent No. 6,337,387 entitled “Differentiation-suppressive polypeptide", issued January 8, 2002), leukemia inhibitory factor (LJF), stem cell factor, or combinations thereof.
  • LJF leukemia inhibitory factor
  • stem cell factor or combinations thereof.
  • one or more populations of embryonic- like stem cells are delivered to a patient in need thereof
  • two or more populations of fresh (never frozen) cells are delivered from a single container or single delivery system.
  • two or more populations of frozen and thawed cells are delivered from a single container or single delivery system.
  • each of two or more populations of fresh (never frozen) cells are transferred to, and delivered from, a single container or single delivery system,
  • each of two or more populations of frozen and thawed cells are transferred to, and delivered from, a single container or single delivery system.
  • each population is delivered from a different TV infusion bag e-g-, from Baxter, Becton-Dickinson, Medcep, National Hospital Products or Terumo).
  • each container e.g., IV infusion bag
  • each container may be "piggybacked" so that their contents are combined or mixed before delivery from a single delivery system.
  • the two or more populations of cells may be fed into and/or mixed within a common flow line (e.g., tubing), or they may be fed into and/or mixed within a common container (e.g., chamber or bag).
  • the two or more populations of cells may be combined before administration, during or at administration or delivered simultaneously.
  • a minimum of 1.7 x 10 7 nucleated cells/kg is delivered to a patient in need thereof.
  • at least 2.5 x 10 7 nucleated cells/kg is delivered to a patient in need thereof.
  • the invention provides a method of treating or preventing a disease or disorder in a subject comprising administering to a subject in which such treatment or prevention is desired a therapeutically effective amount of the embryonic-like stem cells, or supplemented cell populations, of the invention.
  • the invention provides a method of treating or preventing a disease or disorder in a subject comprising administering to a subject in which such treatment or prevention is desired a therapeutically effective amount of the embryonic-like stem cells of the invention.
  • the embryonic-like stem cells of the invention are expected to have an anti- inflammatory effect when administered to an individual experiencing inflammation.
  • the embryonic-like stem cells or supplemental cell populations of the invention may be used to treat any disease, condition or disorder resulting from, or associated with, inflammation.
  • the inflammation may be present in any organ or tissue, for example, muscle; nervous system, including the brain, spinal cord and peripheral nervous system; vascular tissues, including cardiac tissue; pancreas; intestine or other organs of the digestive tract; lung; kidney; liver; reproductive organs; endothelial tissue, or endodermal tissue.
  • the embryonic-like stem cells or supplemented cell populations of the invention may also be used to treat autoimmune or immune system-related disorders, including those associated with inflammation.
  • the invention provides a method of treating an individual having an autoimmune disease or condition, comprising administering to such individual a therapeutically effective amount of the cells or supplemented cell populations of the invention, wherein said disease or disorder can be, but is not limited to, diabetes, amylotrophic lateral sclerosis, myasthenia gravis, diabetic neuropathy or lupus.
  • the embryonic-like stem cells or supplemented cell populations of the invention maybe used to treat immune-related disorders, such as chronic or acute allergies.
  • the disease or disorder includes, but is not limited to, any of the diseases or disorders disclosed herein, including, but not limited to aplastic anemia, myelodysplasia, myocardial infarction, seizure disorder, multiple sclerosis, stroke, hypotension, cardiac arrest, ischemia, inflammation, age-related loss of cognitive function, radiation damage, cerebral palsy, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Leigh disease, AIDS dementia, memory loss, amyotrophic lateral sclerosis (ALS), ischemic renal disease, brain or spinal cord trauma, heart-lung bypass, glaucoma, retinal ischemia, retinal trauma, lysosomal storage diseases, such as Tay-Sachs, Niemann-Pick, Fabry's, Gaucher's, Hunter's, and Hurler's syndromes, as well as other gangliosidoses, mucopolysaccharidoses, glycogenoses, inborn errors of metabolism, adrenole
  • the cells may be used in the treatment of any kind of injury due to trauma, particularly trauma involving inflammation.
  • trauma-related conditions include central nervous system (CNS) injuries, including injuries to the brain, spinal cord, or tissue surrounding the CNS injuries to the peripheral nervous system (PNS); or injuries to any other part of the body.
  • CNS central nervous system
  • PNS peripheral nervous system
  • Such trauma may be caused by accident, or may be a normal or abnormal outcome of a medical procedure such as surgery or angioplasty.
  • the trauma may be related to a rupture or occlusion of a blood vessel, for example, in stroke or phlebitis.
  • the cells may be used in autologous or heterologous tissue regeneration or replacement therapies or protocols, including, but not limited to treatment of corneal epithelial defects, cartilage repair, facial dermabrasion, mucosal membranes, tympanic membranes, intestinal linings, neurological structures (e.g., retina, auditory neurons in basilar membrane, olfactory neurons in olfactory epithelium), burn and wound repair for traumatic injuries of the skin, or for reconstruction of other damaged or diseased organs or tissues.
  • the disease or disorder is aplastic anemia, myelodysplasia, leukemia, a bone marrow disorder or a hematopoietic disease or disorder.
  • the subject is a human.
  • the invention provides a method of treating an individual having a disease, disorder or condition associated with or resulting from inflammation, hi other embodiments, the invention provides a method of treating an individual having a neurological disease, disorder or condition.
  • said neurological disease is ALS.
  • said neurological disease is Parkinson's disease, hi another specific embodiment, said disease is a vascular or cardiovascular disease, hi a more specific embodiment, said disease is atherosclerosis, hi another specific embodiment, said disease is diabetes.
  • the pharmaceutical compositions of the invention comprise an aliquot of umbilical cord blood to which embryonic-like placental stem cells have been added as disclosed above in Section 4.4.
  • a number of the embryonic-like stem cells, or of the supplemented cell populations, once administered, are able to engraft into the host, forming long-term "colonies.” This results in a host that is essentially chimeric. Because chimeras in other genetic contexts are generally more vigorous and resilient, such chimerism is expected enhance the host's health and well-being.
  • the embryonic-like stem cells may be administered not simply to an individual suffering from a specific disease, disorder or condition, but may be administered to an individual in order to increase the individual's overall health and well- being.
  • the embryonic-like stem cells or supplemented cell populations of the invention may be treated prior to administration to an individual with compounds that modulate the activity of TNF- ⁇ .
  • compounds that modulate the activity of TNF- ⁇ .
  • Such compounds are disclosed in detail in copending United States Provisional Application No. 60/372,348, filed April 12, 2002, which disclosure is incorporated herein in its entirety.
  • Preferred compounds are referred to as LMiDs and SelCids, and particularly preferred compounds are available under the trade names ActimidTM and RevimidTM.
  • embryonic-like stem cells of the invention are particularly useful aspects of the embryonic-like stem cells of the invention.
  • embryonic-like stem cells may be taken from a heterologous donor, or a plurality of heterologous donors, and transplanted to an individual in need of such cells, and the transplanted cells will remain within the host indefinitely.
  • This elimination of the need for HLA typing greatly facilitates both the transplantation procedure itself and the identification of donors for transplantation.
  • the embryonic-like stem cells or supplemented cell populations containing them may be HLA matched (donor to recipient) prior to administration.
  • Preconditioning comprises storing the cells in a gas-permeable container of a period of time at approximately -5 to23°C, 0-10°C, or preferably 4-5°C.
  • the period of time may be between 18 hours and 21 days, between 48 hours and 10 days, and is preferably between 3-5 days.
  • the cells may be cryopreserved prior to preconditioning or, preferably, are preconditioned immediately prior to administration.
  • the invention provides a method of treating an individual comprising administering to said individual embryonic-like stem cells collected from at least one donor.
  • the method comprises administering to said individual embryonic-like stem cells that are collected from a plurality of donors and pooled.
  • said embryonic-like stem cells are stem cells taken from a plurality of donors.
  • the dosage units where a "dosage unit” is a collection from a single donor, may be pooled prior to administration, may be administered sequentially, or may be administered alternatively.
  • said embryonic-like stem cells are mixed with, or "spiked” into umbilical cord blood, and the mixture administered to an individual.
  • the ratio of embryonic-like stem cells to cord blood may be at least 20:80, 30:70, 40:60, 50:50, 60:40, 70:30 or 80:20, by number of total nucleated cells.
  • a particularly useful aspect of the invention is the administration of high doses of o stem cells to an individual; such numbers of cells are significantly more effective than the material (for example, bone marrow or cord blood) from which they were derived, h this context, "high dose” indicates 5, 10, 15 or 20 or more times the number of total nucleated cells, including stem cells, particularly embryonic-like stem cells, than would be administered, for example, in a bone marrow transplant.
  • a patient receiving a 5 stem cell infusion for example for a bone marrow transplantation, receives one unit of cells, where a unit is approximately 1 x 10 9 nucleated cells (corresponding to 1-2 X 10 8 stem cells).
  • a patient would be administered 3 billion, 5 billion, 10 billion, 15 billion, 20 billion, 30 billion, 40 billion, 50 billion or more, or, alternatively, 3, 5, 10, 20, 30, 40, or 50 units or more, of total nucleated cells, either 0 embryonic-like stem cells alone, or embryonic-like stem cells spiked into another stem or progenitor cell population (e.g., embryonic-like stem cells spiked into umbilical cord blood).
  • an individual is given 15 units of spiked cord blood, where the unit contains approximately 750 million cord blood cells and 500 million embryonic-like stem cells.
  • the number of nucleated cells 5 administered to an individual is at least five times the number of cells normally administered in a bone marrow replacement
  • the number of nucleated cells administered to an individual is at least ten times the number of cells normally administered in a bone marrow replacement.
  • the number of nucleated cells administered to an individual is at least fifteen times the number of cells normally administered in a bone marrow replacement
  • the total number of nucleated cells, which includes stem cells, administered to an individual is between 1-100 x 10 8 per kilogram of body weight.
  • the number of total nucleated cells administered is at least 5 billion cells.
  • the total number of nucleated cells administered is at least 15 billion cells.
  • said embryonic-like stem cells and said cord blood are mixed immediately prior to (i.e., within five minutes of) administration to said individual.
  • said embryonic-like stem cells and said cord blood are mixed at a point in time more than five minutes prior to administration to said individual.
  • the embryonic-like stem cells are cryopreserved and thawed prior to administration to said individual, hi another embodiment, said embryonic- like stem cells and said cord blood are mixed to form a supplemented cell population at a point in time more than twenty-four hours prior to administration to said individual, wherein said supplemented cell population has been cryopreserved and thawed prior to said administration, hi another embodiment, said embryonic-like stem cells and/or supplemented cell populations may be administered more than once, hi another embodiment, said embryonic-like stem cells and/or supplemented cell populations are preconditioned by storage from between 18 hours and 21 days prior to administration, hi a more specific embodiment, the cells are preconditioned for 48 hours to 10 days prior to administration.
  • said cells are preconditioned for 3-5 days prior to transplantation.
  • said embryonic-like stem cells are not HLA typed prior to administration to an individual.
  • said embryonic-like stem cells are primarily (i.e., > 50%) CD34 + cells, hi a more specific embodiment of the method, said embryonic-like stem cells are primarily CD34 + 33 + stem cells.
  • Therapeutic or prophylactic treatment of an individual with embryonic-like stem cells or supplemented cell populations containing them maybe considered efficacious if the disease, disorder or condition is measurably improved in any way. Such improvement may be shown by a number of indicators.
  • Measurable indicators include, for example, detectable changes in a physiological condition or set of physiological conditions associated with a particular disease, disorder or condition (including, but not limited to, blood pressure, heart rate, respiratory rate, counts of various blood cell types, levels in the blood of certain proteins, carbohydrates, lipids or cytokines or modulation expression of genetic markers associated with the disease, disorder or condition).
  • Treatment of an individual with the stem cells or supplemented cell populations of the invention would be considered effective if any one of such indicators responds to such treatment by changing to a value that is within, or closer to, the normal value.
  • the normal value may be established by normal ranges that are known in the art for various indicators, or by comparison to such values in a control.
  • the efficacy of a treatment is also often characterized in terms of an individual ' s impressions and subj ective feeling of the individual ' s state of health. Improvement therefore may also be characterized by subjective indicators, such as the individual's subjective feeling of improvement, increased well-being, increased state of health, improved level of energy, or the like, after administration of the stem cells or supplemented cell populations of the invention.
  • the embryonic-like stem cells and supplemented cell populations of the invention may be administered to a patient in any pharmaceutically or medically acceptable manner, including by injection or transfusion.
  • the cells or supplemented cell populations may be contain, or be contained in any pharmaceutically-acceptable carrier (See Section 4.8).
  • the embryonic-like stem cells or supplemented cell populations may be carried, stored, or transported in any pharmaceutically or medically acceptable container, for example, a blood o bag, transfer bag, plastic tube or vial.
  • the invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of 5 the invention.
  • container(s) can be: an apparatus for cell culture, one or more containers filled with a cell culture medium or one or more components of a cell culture medium, an apparatus for use in delivery of the compositions of the invention, e.g., an apparatus for the intravenous injection of the compositions of the invention, and/or a notice in the form prescribed by a governmental agency regulating the 0 manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration, hi a specific embodiment, the kit comprises one or more containers filled with embryonic-like stem cells of the invention and one or more different containers filled with stem cells, e.g., umbilical cord blood, as disclosed above.
  • stem cells e.g., umbilical cord blood
  • the kit comprises a mixture of stem cells, e.g., cord blood cells, supplemented with embryonic-like stem cells contained within one bag or container.
  • the kit comprises a population of cord blood cells and a population of embryonic-like stem cells that are contained within two separate bags or containers.
  • the kit comprises a "two bag" composition wherein the bag containing the cord blood cells and the bag containing the embryonic-like stem cells is mixed prior to, or at the time of, administration to a patient in need thereof.
  • the kit comprises a population of cord blood cells and a population of embryonic-like stem cells that are contained within two separate bags or containers and that are administered separately (e.g., simultaneously or sequentially) to a patient, wherein the mixing of the two cell populations occurs in vivo.
  • the kit provides a population of cord blood cells and a population of embryonic-like stem cells that are physically mixed prior to administration.
  • the kit comprises a container containing a growth factor, e.g.,GM-CSF, IL-4, Flt3L, CD40L, IFN-alpha, TNF-alpha, JFN-gamma, IL-2, LL-6, retinoic acid, basic fibroblast growth factor, TGF-beta-1, TGF-beta-3, hepatocyte growth factor, epidermal growth factor, cardiotropin-1, angiotensinogen, angiotensin I (Al), angiotensin ⁇ (AJJ), ATI AT 2 type 2 receptor agonists, or analogs or fragments thereof.
  • a growth factor e.g.,GM-CSF, IL-4, Flt3L, CD40L, IFN-alpha, TNF-alpha, JFN-gamma, IL-2, LL-6, retinoic acid, basic fibroblast growth factor, TGF-beta-1, TGF-beta-3, hepatocyte growth factor, epidermal
  • the two populations are physically mixed and then treated with the growth factor comprised in the kit, to induce cell differentiation, prior to administration to the patient.
  • the cord blood cells and/or the embryonic-like stem cells are treated with the growth factor comprised in the kit, to induce cell differentiation and then physically mixed prior to administration to the patient.
  • This example describes the analysis of the cell types recovered from the effluent perfusate of a placenta cultured according to the methods of the invention.
  • phosphate buffered saline solution PBS
  • a 10 ml portion was collected and centrifuged for 25 minutes at 3000 rpm (revolutions per minute).
  • the effluent was divided into four tubes and placed in an ice bath.
  • 2.5 ml of a 1% fetal calf serum (FCS) solution in PBS was added and the tubes were centrifuged (140 minutes x 10 g (acceleration due to gravity)).
  • FCS 1% fetal calf serum
  • the pellet was resuspended in 5 ml of 1% FCS and two tubes were combined.
  • the total mononucleocytes were calculated by adding the total lymphocytes and the total monocytes, and then multiplying the result by the total cell suspension volume.
  • the following table discloses the types of cells obtained by perfusion of a cultured placenta according to the methods described hereinabove.
  • Total cell number of PP after Ficoll was 5.3 X 10 8 and number of CB before processing is 6.3 X 10 8 .
  • Lym% indicates percent of lymphocytes; MID% indicates percent of midrange white blood cells; and GRA% indicates percent of granulocytes.
  • the following example describes an analysis of cells obtained by perfusion and incubation of placenta according to the methods of the invention.
  • Placenta donors were recruited from expectant mothers that enrolled in private umbilical cord blood banking programs and provided informed consent permitting the use of the exsanguinated placenta following recovery of cord blood for research purposes.
  • Donor data may be confidential.
  • These donors also permitted use of blinded data generated from the normal processing of their umbilical cord blood specimens for cryopreservation. This allowed comparison between the composition of the collected cord blood and the effluent perfusate recovered using the experimental method described below.
  • placenta Following exsanguination of cord blood from the umbilical cord and placenta is stored at room temperature and delivered to the laboratory within four to twenty-four hour, according to the methods described hereinabove, the placenta was placed in a sterile, insulated container at room temperature and delivered to the laboratory within 4 hours of birth. Placentas were discarded if, on inspection, they had evidence of physical damage such as fragmentation of the organ or avulsion of umbilical vessels. Placentas were maintained at room temperature (23 ⁇ 2°C) or refrigerated (4°C) in sterile containers for 2 to 20 hours.
  • the placentas were immersed and washed in sterile saline at 25 ⁇ 3 °C to remove any visible surface blood or debris.
  • the umbilical cord was transected approximately 5 cm from its insertion into the placenta and the umbilical vessels were cannulated with TEFLON® or polypropylene catheters connected to a sterile fluid path allowing bi-directional perfusion of the placenta and recovery of the effluent fluid.
  • the donor placentas were processed at room temperature within 12 to 24 hours after delivery. Before processing, the membranes were removed and the maternal site washed
  • the umbilical vessels were cannulated with catheters made from 20 gauge Butterfly needles use for blood sample collection.
  • the donor placentas were maintained under varying conditions such as maintenance at 5-37° 5% C0 2 , pH 7.2 to 7.5, preferably pH 7.45, in an attempt to simulate and sustain a physiologically compatible environment for the proliferation and recruitment of residual
  • Placentas were then perfused with heparinized (2U/ml) Dulbecco's modified Eagle
  • H.DMEM H.DMEM
  • 35 nucleated cells were then isolated by Ficoll-Hypaque density gradient centrifugation and after washing, resuspended in H.DMEM.
  • aliquots of 5- 10 x 10 6 cells were placed in each of several T-75 flasks and cultured with commercially available Mesenchymal Stem Cell Growth Medium (MSCGM) obtained from BioWhittaker, and placed in a tissue culture incubator (37°C, 5% C0 2 ). After 10 to 15 days, the non-adherent cells were removed by washing with PBS, which was then replaced by 5 MSCGM.
  • the flasks were examined daily for the presence of various adherent cell types and in particular, for identification and expansion of clusters of fibroblastoid cells.
  • the detached fibroblastoid cells were harvested following trypsinization and trypsin neutralization, using Trypsin Neutralizing Solution (TNS, BioWhittaker). The cells were washed in H.DMEM and resuspended in MSCGM.
  • Flow cytometry was carried out using a Becton-Dickinson FACSCalibur instrument and FITC and PE labeled monoclonal antibodies (mAbs), selected on the basis of known
  • markers for bone marrow-derived MSC (mesenchymal stem cells), were purchased from B.D. and Caltag laboratories (South San Francisco, CA.), and SH2, SH3 and SH4 antibody producing hybridomas were obtained from and reactivities of the mAbs in their cultured supernatants were detected by FITC or PE labeled F(ab)'2 goat anti-mouse antibodies. Lineage differentiation was carried out using commercially available induction and
  • the placenta-derived embryonic-like stem cells in contrast to their earlier phase, adhered within hours, assumed characteristic fibroblastoid shape, and formed a growth pattern identical to the reference bone marrow-derived MSC.
  • the loosely bound mononuclear cells were washed out and the cultures remained homogeneous and devoid of any visible non- fibroblastoid cell contaminants.
  • CD-34, CD-38, and other stem cell-associated surface markers on early and late fraction purified mononuclear cells was assessed by flow cytometry. Recovered, sorted cells were washed in PBS and then double-stained with antiCD34 phycoerythrin and anti-CD38 fluorescein isothiocyanate (Becton Dickinson, Mountain View, CA).
  • Cell isolation was achieved by using magnetic cell separation, such as for example, Auto Macs (Miltenyi).
  • CD 34+ cell isolation is performed first.
  • the following example provides a formula of the preferred perfusate solution for the cultivation of isolated placentas.
  • the above-composition is a perfusate that may be used at a variety of temperatures to perfuse placenta. It should be noted that additional components such as antibiotics, anticoagulant and other growth factors may be used in the perfusate or culture media.
  • Cord blood cells and/or embryonic-like stem cells are induced to differentiate into a particular cell type by exposure to a growth factor.
  • Growth factors that are used to induce induction include, but are not limited to: GM-CSF, LL-4, Flt3L, CD40L, IFN-alpha, TNF- alpha, JFN-gamma, LL-2, IL-6, retinoic acid, basic fibroblast growth factor, TGF-beta-1, TGF-beta-3, hepatocyte growth factor, epidermal growth factor, cardiotropin-1, angiotensinogen, angiotensin I (Al), angiotensin ⁇ (AS), AH AT 2 type 2 receptor agonists, or analogs or fragments thereof.
  • Placental stem cells are grown for 24 hr in preinduction media consisting of DMEM/20% FBS and 1 mM beta-mercaptoethanol.
  • Neuronal induction media consisting of DMEM and 1-10 mM betamercaptoethanol is added.
  • induction media consisting of DMEM/2% DMSO/200 ⁇ M o butylated hydroxyanisole may be used to enhance neuronal differentiation efficiency.
  • morphologic and molecular changes may occur as early as 60 minutes after exposure to serum-free media and betamercaptoethanol (Woodbury et al., J. Neurosci. Res., 61:364-370).
  • RT/PCR maybe used to assess the expression 5 of e.g., nerve growth factor receptor and neurofilament heavy chain genes.
  • This example describes the induction of cord blood cells and/or embryonic-like stem cells to differentiate into adipocytes.
  • the following protocol is employed to induce 0 adipogenic differentiation:
  • Placental stem cells are grown in MSCGM (Bio Whittaker) or DMEM supplemented with 15% cord blood serum.
  • Each cycle consists of feeding the placental stem cells with Adipogenesis Induction Medium (Bio Whittaker) and 5 culturing the cells for 3 days (at 37°C, 5% C0 2 ), followed by 1-3 days of culture in
  • Adipogenesis Maintenance Medium (Bio Whittaker). An induction medium is used that contains 1 ⁇ M dexamethasone, 0.2 mM indomethacin, 0.01 mg/ml insulin, 0.5 mM TBMX, DMEM-high glucose, FBS, and antibiotics.
  • the cells are cultured for an 0 additional 7 days in adipogenesis maintenance medium, replacing the medium every
  • Adipogenesis may be assessed by the development of multiple intracytoplasmic lipid vesicles that can be easily observed using the lipophilic stain oil red O. RT PCR assays are employed to examine the expression of lipase and fatty acid binding protein genes. 5.4.3 Induction Of Differentiation Into Chondrocytes
  • This example describes the induction of cord blood cells and/or embryonic-like stem cells to differentiate into chondrocytes.
  • the following protocol is employed to induce chondrogenic differentiation:
  • Placental stem cells are maintained in MSCGM (Bio Whittaker) or DMEM supplemented with 15% cord blood serum.
  • Placental stem cells are aliquoted into a sterile polypropylene tube. The cells are centrifuged (150 x g for 5 minutes), and washed twice in Incomplete Chondrogenesis Medium (Bio Whittaker).
  • the cells are resuspended in Complete Chondrogenesis Medium (Bio Whittaker) containing 0.01 ⁇ g/ml TGF-beta-3 at a concentration of 5 x 10(5) cells/ml.
  • the cell pellets are fed every 2-3 days with freshly prepared complete chondrogenesis medium.
  • Pellets are maintained suspended in medium by daily agitation using a low speed vortex.
  • Chondrogenesis may be characterized by e.g. , observation of production of esoinophilic ground substance, assessing cell morphology, an/or RT PCR for examining collagen 2 and collagen 9 gene expression.
  • This example describes the induction of cord blood cells and/or embryonic-like stem cells to differentiate into osteocytes.
  • the following protocol is employed to induce osteogenic differentiation:
  • Adherent cultures of placental stem cells are cultured in MSCGM (Bio Whittaker) or DMEM supplemented with 15% cord blood serum.
  • Osteogenic differentiation is induced by replacing MSCGM with Osteogenic Induction Medium (Bio Whittaker) containing 0.1 ⁇ M dexamethasone, 0.05 mM ascorbic acid-2-phosphate, 10 mM beta glycerophosphate. 4. Cells are fed every 3-4 days for 2-3 weeks with Osteogenic Induction Medium.
  • This example describes the induction of cord blood cells and/or embryonic-like stem cells to differentiate into hepatocytes.
  • the following protocol is employed to induce hepatogenic differentiation:
  • Placental stem cells are cultured in DMEM/20% CBS supplemented with hepatocyte growth factor, 20 ng/ml; and epidermal growth factor, 100 ng/ml. KnockOut Serum Replacement may be used in lieu of FBS.
  • IL-6 50 ng/ml is added to induction flasks.
  • This example describes the induction of cord blood cells and/or embryonic-like stem cells to differentiate into pancreatic cells.
  • the following protocol is employed to induce pancreatic differentiation:
  • Placental stem cells are cultured in DMEM/20%) CBS, supplemented with basic fibroblast growth factor, 10 ng/ml; and transforming growth factor beta-1, 2 ng/ml. KnockOut Serum Replacement may be used in lieu of CBS.
  • Conditioned media from nestin-positive neuronal cell cultures is added to media at a 50/50 concentration.
  • Differentiation is characterized by assaying for insulin protein or insulin gene expression by RT/PCR.
  • This example describes the induction of cord blood cells and/or embryonic-like stem cells to differentiate into cardiac cells.
  • the following protocol is employed to induce myogenic differentiation:
  • Placental stem cells are cultured in DMEM/20% CBS, supplemented with retinoic acid, 1 ⁇ M; basic fibroblast growth factor, 10 ng/ml; and transforming growth factor beta-1, 2 ng/ml; and epidermal growth factor, 100 ng/ml.
  • KnockOut Serum 1 ⁇ M
  • basic fibroblast growth factor 10 ng/ml
  • transforming growth factor beta-1 2 ng/ml
  • epidermal growth factor 100 ng/ml.
  • placental stem cells are cultured in DMEM/20%) CBS supplemented with 50 ng/ml Cardiotropin-1 for 24 hours. 3. Alternatively, placental stem cells are maintained in protein-free media for 5-7 days, then stimulated with human myocardium extract (escalating dose analysis).
  • Myocardium extract is produced by homogenizing 1 gm human myocardium in 1%
  • HEPES buffer supplemented with 1% cord blood serum. The suspension is incubated for 60 minutes, then centrifuged and the supernatant collected. 4. Cells are cultured for 10- 14 days, refeeding every 3 -4 days.
  • the embryonic-like stem cells, the cord blood cells and/or the populations of cord blood cells spiked with embryonic-like stem cells are characterized prior to and/or after differentiation by measuring changes in morphology and cell surface markers using techniques such as flow cytometry and immunocytochemistry, and measuring changes in gene expression using techniques, such as PCR.
  • Cells that have been exposed to growth factors and/or that have differentiated are characterized by the presence or absence of the following cell surface markers: CD10+, CD29+, CD34-, CD38-, CD44+, CD45-, CD54+, CD90+, SH2+, SH3+, SH4+, SSEA3-, SSEA4-, OCT-4+, and ABC-p+.
  • the embryonic-like stem cell are characterized, prior to differentiation, by the presence of cell surface markers OCT-4+, APC-p+, CD34- and CD38-. Stem cells bearing these markers are as versatile (e.g., pluripotent) as human embryonic stem cells.
  • Cord blood cells are characterized, prior to differentiation, by the presence of cell surface markers CD34+ and CD38+. Differentiated cells derived from embryonic-like stem cells, cord blood cells and/or a populations of cord blood cells spiked with embryonic-like stem cells preferably do not express these markers.
  • ALS Amyotrophic Lateral Sclerosis
  • S-ALS sporadic
  • F-ALS hereditary
  • ALS occurs when specific nerve cells in the brain and spinal cord that control voluntary movement gradually degenerate.
  • the cardinal feature of ALS is the loss of spinal motor neurons which causes the muscles under their control to weaken and waste away leading to paralysis.
  • ALS manifests itself in different ways, depending on which muscles weaken first. ALS strikes in mid-life with men being one-and-a-half times more likely to have the disease as women. ALS is usually fatal within five years after diagnosis.
  • ALS has both familial and sporadic forms, and the familial forms have now been linked to several distinct genetic loci. Only about 5-10% of ALS cases are familial. Of these, 15-20% are due to mutations in the gene encoding Cu/Zn superoxide dismutase 1 (SOD1). These appear to be "gain-of-function" mutations that confer toxic properties on the enzyme.
  • SOD1 Cu/Zn superoxide dismutase 1
  • the method involves intravenous infusion through a peripheral, temporary angiocatheter.
  • ALS An individual having ALS is first assessed by the performance of standard laboratory analyses. Such analyses may include a metabolic profile; CDC with differential; lipid profile; fibrinogen level; ABO rH typing of the blood; liver function tests; and determination of BUN/creatine levels. Individuals are instructed the day prior to the transplant to take the following medications: diphenhydramine (BenadrylTM), 25 mg t.i.d, and prednisone, 10 mg. The embryonic-like stem cells, either alone or spiked into cord blood, are taken from cryopreserved stock, thawed, and maintained for approximately two days prior to transplantation at a temperature of approximately 5°C.
  • the individual is transplanted at an outpatient clinical center which has all facilities necessary for intravenous infusion, physiological monitoring and physical observation. Approximately one hour prior to transplantation, the individual receives diphenhydramine (BenadrylTM), 25 mg x 1 P.O., and prednisone, 10 mg x 1 P.O. This is precautionary, and is meant to reduce the likelihood of an acute allergic reaction.
  • an 18 G indwelling peripheral venous line is places into one of the individual's extremities, and is maintained open by infusion of D5 Vi normal saline + 20 mEq KC1 at a TKO rate.
  • the individual is examined prior to transplantation, specifically to note heart rate, respiratory rate, temperature. Other monitoring may be performed, such as an electrocardiogram and blood pressure measurement.
  • Embryonic-like stem cells are then infused at a rate of 1 unit per hour in a total delivered fluid volume of 60 ml, where a unit is approximately 1-2 10 9 total nucleated cells.
  • the unit of embryonic-like stem cells is delivered in cord blood having a total fluid volume of 60 ml.
  • the ratio of the number of embryonic-like stem cells to stem cells in the cord blood is at least 2: 1.
  • the administered unit may also consist of cord blood alone. Based upon data from pre-clinical studies in mice, a total of 2.0-2.5 x 10 8 cells per kilogram of body weight should be administered. For example, a 70 kilogram individual would receive approximately 14-18 x 10 9 total nucleated cells. The individual should be monitored for signs of allergic response or hypersensitivity, which are signals for immediate cessation of infusion.
  • the individual should be monitored in a recumbent position for at least 60 minutes, whereupon he or she may resume normal activities.
  • the infusion protocol outlined in Example 5 may be used to administer the embryonic-like stem cells, either alone or spiked into umbilical cord blood, to a patient having atherosclerosis.
  • the embryonic-like stem cells or supplemented cell populations may be administered to asymptomatic individuals, individuals that are candidates for angioplasty, or to patients that have recently (within one week) undergone cardiac surgery.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

L'invention concerne des compositions et des procédés visant à utiliser des cellules souches de type embryonnaire dérivées de placenta post-partum, en combinaison avec des compositions de sang ombilical classiques ou autres cellules souches ou progénitrices. Les cellules souches de type embryonnaire considérées peuvent être utilisées isolément ou en combinaison avec d'autres populations de cellules souches. Aux fins de l'invention, on peut combiner les cellules souches de type embryonnaire considérées avec d'autres populations de cellules souches, y compris mais pas seulement le sang ombilical, les cellules souches hématopoïétiques foetales et néonatales et les cellules progénitrices, ou les cellules souches et progénitrices humaines dérivées de moelle osseuse. Les cellules souches de type embryonnaire décrites et les populations mixtes de cellules souches de type embryonnaire et de cellules souches ont une multitude d'utilisations et d'applications, y compris mais pas seulement les utilisations thérapeutiques aux fins de transplantation, de traitement et de prévention des maladies, de diagnostic et de recherche.
EP03739817A 2002-02-13 2003-02-13 Cellules souches de type embryonnaire derivees de placenta mammalien post-partum, utilisations, et procedes de traitement a base de cellules de ce type Ceased EP1482787A4 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP10155478A EP2186407A1 (fr) 2002-02-13 2003-02-13 Cellules souches de type embryonnaire dérivées de placenta mammalien post-partum, utilisations, et procédés de traitement à base de cellules de ce type
EP10184356A EP2301343A1 (fr) 2002-02-13 2003-02-13 Cellules souches de type embryonnaire dérivées de placenta mammalien post-partum, utilisations, et procédés de traitement à base de cellules de ce type
EP10185142A EP2292091A1 (fr) 2002-02-13 2003-02-13 Cellules souches de type embryonnaire dérivées de placenta mammalien post-partum, utilisations, et procédés de traitement à base de cellules de ce type

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/076,180 US20030032179A1 (en) 2000-12-06 2002-02-13 Post-partum mammalian placenta, its use and placental stem cells therefrom
US76180 2002-02-13
US43729202P 2002-12-31 2002-12-31
US437292P 2002-12-31
PCT/US2003/004539 WO2003068937A2 (fr) 2002-02-13 2003-02-13 Cellules souches de type embryonnaire derivees de placenta mammalien post-partum, utilisations, et procedes de traitement a base de cellules de ce type

Publications (2)

Publication Number Publication Date
EP1482787A2 EP1482787A2 (fr) 2004-12-08
EP1482787A4 true EP1482787A4 (fr) 2006-02-15

Family

ID=42186393

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03739817A Ceased EP1482787A4 (fr) 2002-02-13 2003-02-13 Cellules souches de type embryonnaire derivees de placenta mammalien post-partum, utilisations, et procedes de traitement a base de cellules de ce type

Country Status (10)

Country Link
EP (1) EP1482787A4 (fr)
JP (2) JP2005517402A (fr)
KR (2) KR20110036114A (fr)
AU (2) AU2003216286B2 (fr)
CA (1) CA2476553A1 (fr)
IL (2) IL163439A (fr)
MX (1) MXPA04007732A (fr)
NZ (1) NZ534643A (fr)
WO (1) WO2003068937A2 (fr)
ZA (1) ZA200406356B (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430989A1 (fr) 2000-12-06 2002-06-13 Robert J. Hariri Technique de recueil de cellules souches placentaires
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
AU2004212009B2 (en) * 2003-02-13 2010-07-29 Celularity Inc. Use of umbilical cord blood to treat individuals having a disease, disorder or condition
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US8491883B2 (en) * 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
JP4950661B2 (ja) 2003-06-27 2012-06-13 エチコン、インコーポレイテッド 分娩後由来細胞類を使用する、神経組織の再生および修復
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US8088585B2 (en) 2003-10-31 2012-01-03 Children's Medical Center Corporation Methods for purifying hematopoietic stem cells
US7816137B2 (en) 2004-01-30 2010-10-19 Lifecord Inc. Method for isolating and culturing multipotent progenitor cells from umbilical cord blood
WO2005108559A2 (fr) * 2004-04-23 2005-11-17 Bioe, Inc. Cellules précurseurs de plusieurs lignages
US8309070B2 (en) 2004-05-17 2012-11-13 Regents Of The University Of Minnesota Use of umbilical cord blood stem cells to treat ischemic event
WO2006015214A2 (fr) * 2004-07-29 2006-02-09 Steenblock Research Institute, Inc. Composition de cellules souches de cordon ombilical et methode de traitement de maladies neurologiques
CA2504451A1 (fr) * 2004-08-10 2006-02-10 Geron Corporation Vaccins a cellules dendritiques faits de cellules souches embryonnaires pour le traitement du cancer
EP1789534B1 (fr) 2004-08-16 2014-08-06 CellResearch Corporation Pte Ltd Isolement de cellules souches/progenitrices issues de la membrane amniotique du cordon ombilical
WO2006071777A2 (fr) * 2004-12-23 2006-07-06 Ethicon Incorporated Reparation et regeneration de tissus mous au moyen de cellules derivees du post-partum et produits cellulaires
WO2006071773A2 (fr) * 2004-12-23 2006-07-06 Ethicon Incoporated Traitement de maladies osteochondrales utilisant des cellules derivees de post-partum et des produits de ceux-ci
CA2592435C (fr) 2004-12-23 2017-03-28 Ethicon, Incorporated Traitement de l'ictus cerebral et d'autres troubles neurodegeneratifs aigus a base de cellules tirees de tissus puerperaux
EP1807509B1 (fr) * 2005-08-26 2009-11-18 Seoul National University Industry Foundation Cellules souches multipotentes isolees du sang de cordon ombilical et agent therapeutique cellulaire contenant ces cellules en vue de traiter une maladie ischemique
JP2007106760A (ja) * 2005-09-16 2007-04-26 Kenji Yoshida 造血幹細胞増殖剤
US20090123560A1 (en) * 2005-09-16 2009-05-14 Kenji Yoshida Hematopoietic Stem Cell Proliferation Inducing Agent
US9388382B2 (en) 2005-10-05 2016-07-12 The Board Of Trustees Of The University Of Illinois Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
EP1941031B1 (fr) 2005-10-05 2013-12-25 The Board Of Trustees Of The University Of Illinois Cellules souches de type embryonnaire isolées dérivées du sang du cordon ombilical humain
EP1957633B1 (fr) * 2005-10-13 2013-12-18 Anthrogenesis Corporation Immunomodulation realisee avec des cellules souches placentaires
EP1934334A1 (fr) 2005-10-13 2008-06-25 Anthrogenesis Corporation Production d'oligodendrocytes a partir de cellules souches derivees du placenta
CN103113463B (zh) * 2005-12-13 2015-02-18 国立大学法人京都大学 核重新编程因子
JP5289970B2 (ja) 2005-12-16 2013-09-11 エシコン・インコーポレイテッド 組織適合性不適合な移植における逆免疫反応を抑制するための組成物および方法
ES2628129T3 (es) * 2005-12-28 2017-08-01 DePuy Synthes Products, Inc. Tratamiento de la enfermedad vascular periférica utilizando células derivadas del posparto
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
CN103525758B (zh) 2005-12-29 2018-02-13 人类起源公司 胎盘干细胞群
KR20080097190A (ko) 2005-12-29 2008-11-04 안트로제네시스 코포레이션 태반 줄기세포의 수집과 보존을 위한 개선된 조성물과 이조성물의 이용 방법
ZA200804718B (en) * 2005-12-29 2010-04-28 Anthrogenesis Corp Co-culture of placental stem cells and stem cells from a second source
AU2014201181B2 (en) * 2005-12-29 2017-07-20 Celularity Inc. Placental stem cell populations
US9944900B2 (en) 2006-01-18 2018-04-17 Hemacell Perfusion Pulsatile perfusion extraction method for non-embryonic pluripotent stem cells
WO2007121443A2 (fr) * 2006-04-17 2007-10-25 Bioe, Inc. Différenciation des cellules progénitrices à lignées multiples et cellules épithéliales respiratoires
BRPI0711599B8 (pt) 2006-05-11 2021-07-27 Hli Cellular Therapeutics Llc métodos para coleta e de uso de células-tronco de sangue de cordão umbilical de placenta
CA2666789C (fr) 2006-10-18 2016-11-22 Yong Zhao Cellules souches de type embryonnaire derivees du sang peripherique d'un etre humain adulte et procedes d'utilisation associes
KR100812544B1 (ko) * 2006-10-19 2008-03-13 재단법인서울대학교산학협력재단 제대혈 유래 다분화능 줄기세포 및 이를 함유하는 허혈성괴사질환 치료용 세포치료제
DK2084268T3 (en) * 2006-10-23 2019-01-21 Celularity Inc METHODS AND COMPOSITIONS FOR TREATING BONE JOIN DEFECTS WITH PLACENTACLE POPULATIONS
CN101688177A (zh) 2007-02-12 2010-03-31 人类起源公司 来自贴壁胎盘干细胞的肝细胞和软骨细胞；以及cd34+、cd45-胎盘干细胞富集的细胞群
AU2014203165B2 (en) * 2007-02-12 2016-08-11 Celularity Inc. Treatment of inflammatory diseases using placental stem cells
SI2120977T1 (sl) * 2007-02-12 2014-01-31 Anthrogenesis Coroporation Zdravljenje vnetnih bolezni z uporabo placentarnih matičnih celic
US8673547B2 (en) 2007-03-08 2014-03-18 Hemacell Perfusion, Inc. Method for isolation of afterbirth derived cells
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
AU2013267050B2 (en) * 2007-09-19 2016-01-07 Pluristem Ltd. Adherent cells from adipose or placenta tissues and use thereof in therapy
CN107028981B (zh) * 2007-09-19 2021-04-20 普拉里斯坦有限公司 来自脂肪或胎盘组织的粘附细胞及其在治疗中的用途
KR20180059583A (ko) * 2007-09-26 2018-06-04 안트로제네시스 코포레이션 인간 태반 관류액으로부터의 혈관형성 세포
WO2009045360A2 (fr) 2007-09-28 2009-04-09 Celgene Cellular Therapeutics Elimination des tumeurs au moyen d'un perfusat placentaire humain et de cellules tueuses naturelles intermediaires provenant d'un placenta humain
US20090136471A1 (en) * 2007-11-07 2009-05-28 Anthrogenesis Corporation Treatment of premature birth complications
KR20210010648A (ko) 2008-08-20 2021-01-27 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
JP5518893B2 (ja) 2008-12-19 2014-06-11 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 肺ならびに肺の疾患および障害の治療
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
WO2010111663A1 (fr) 2009-03-26 2010-09-30 Ethicon, Inc. Cellules tissulaires du cordon ombilical humain utilisées comme thérapie pour la maladie d'alzheimer
US8586360B2 (en) 2009-07-02 2013-11-19 Anthrogenesis Corporation Method of producing erythrocytes without feeder cells
EP3284818B1 (fr) 2010-01-26 2022-03-09 Celularity Inc. Traitement de cancers des os au moyen de cellules souches placentaires
EA201290577A1 (ru) 2010-01-26 2013-06-28 Стем Селз Спин С.А. Клеточный гомогенат из стволовых клеток, полученных из растущих рогов оленя, способ его получения и применения
NZ602808A (en) 2010-04-07 2014-10-31 Anthrogenesis Corp Angiogenesis using placental stem cells
KR20190108599A (ko) 2010-07-13 2019-09-24 안트로제네시스 코포레이션 천연 킬러 세포의 생성 방법
WO2012092485A1 (fr) 2010-12-31 2012-07-05 Anthrogenesis Corporation Amélioration de l'efficacité de cellules souches placentaires sous l'effet de molécules d'arn modulateur
AU2012262273B2 (en) 2011-06-01 2017-09-14 Celularity Inc. Treatment of pain using placental stem cells
CA2869681A1 (fr) 2011-12-23 2013-06-27 Advanced Technologies And Regenerative Medicine, Llc Detection de cellules extraites du tissu du cordon ombilical chez l'homme
CN105142651A (zh) 2013-02-05 2015-12-09 人类起源公司 来自胎盘的自然杀伤细胞
PL2968420T3 (pl) * 2013-03-14 2019-08-30 Celularity, Inc. Zastosowanie komórek macierzystych łożyska do leczenia ostrego uszkodzenia nerek
WO2014140921A2 (fr) 2013-03-15 2014-09-18 Larsson Marcus Kare Torleif Cellules, procédés et appareils de collecte de sang du cordon ombilical et d'isolation des cellules
SG11201603166UA (en) * 2013-10-24 2016-05-30 Ospedale San Raffaele Srl Method
FR3035407B1 (fr) 2015-04-23 2022-06-17 Francais Du Sang Ets Procede de conservation de cellules, tissus ou organes en hypothermie
FR3040860B1 (fr) * 2015-09-10 2020-05-15 Universite de Bordeaux Milieu de conservation injectable pour la conservation de cellules du sang placentaire, de la moelle osseuse et du sang peripherique
US11542473B2 (en) 2016-10-21 2023-01-03 Amniotics Ab Methods and compositions for generating hematopoietic cells
KR20220104682A (ko) 2019-10-18 2022-07-26 암니오틱스 아베 양수로부터 양수 간엽 줄기 세포 및 이로부터 유도된 세포를 얻기 위한 프로세스 및 장치

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021767A2 (fr) * 1999-09-24 2001-03-29 Morphogen Pharmaceuticals, Inc. Cellules souches embryonnaires totipotentes
WO2002046373A1 (fr) * 2000-12-06 2002-06-13 Hariri Robert J Technique de recueil de cellules souches placentaires
WO2002064755A2 (fr) * 2001-02-14 2002-08-22 Anthrogenesis Corporation Placenta post-gravidique de mammifere, son utilisation et cellules souches placentaires correspondantes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004681B1 (en) * 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
GB9308271D0 (en) * 1993-04-21 1993-06-02 Univ Edinburgh Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
CN1170926C (zh) * 1994-11-16 2004-10-13 安姆根有限公司 干细胞因子和可溶性白介素-6受体在血细胞生成多能性细胞体外扩增中的应用
US5916202A (en) * 1996-08-30 1999-06-29 Haswell; John N. Umbilical cord blood collection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021767A2 (fr) * 1999-09-24 2001-03-29 Morphogen Pharmaceuticals, Inc. Cellules souches embryonnaires totipotentes
WO2002046373A1 (fr) * 2000-12-06 2002-06-13 Hariri Robert J Technique de recueil de cellules souches placentaires
WO2002064755A2 (fr) * 2001-02-14 2002-08-22 Anthrogenesis Corporation Placenta post-gravidique de mammifere, son utilisation et cellules souches placentaires correspondantes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN J ET AL: "Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats.", STROKE; A JOURNAL OF CEREBRAL CIRCULATION. NOV 2001, vol. 32, no. 11, November 2001 (2001-11-01), pages 2682 - 2688, XP002354543, ISSN: 1524-4628 *
QIAN YE ET AL: "Recovery of placental-derived adherent cells with mesenchymal stem cell characteristics", BLOOD, vol. 98, 2001, pages 147B, XP009026843 *

Also Published As

Publication number Publication date
ZA200406356B (en) 2006-06-28
JP2010059193A (ja) 2010-03-18
KR20040094426A (ko) 2004-11-09
JP2005517402A (ja) 2005-06-16
IL163439A (en) 2011-03-31
NZ534643A (en) 2010-06-25
AU2003216286A1 (en) 2003-09-04
EP1482787A2 (fr) 2004-12-08
MXPA04007732A (es) 2004-10-15
WO2003068937A3 (fr) 2004-04-22
AU2003216286B2 (en) 2008-08-28
AU2008249204A1 (en) 2008-12-18
IL207763A0 (en) 2010-12-30
IL207763A (en) 2014-07-31
AU2008249204B2 (en) 2011-03-10
CA2476553A1 (fr) 2003-08-21
KR101176146B1 (ko) 2012-08-22
KR20110036114A (ko) 2011-04-06
WO2003068937A2 (fr) 2003-08-21

Similar Documents

Publication Publication Date Title
US7311905B2 (en) Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
AU2003216286B2 (en) Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
AU2004212009B2 (en) Use of umbilical cord blood to treat individuals having a disease, disorder or condition
EP2316919B1 (fr) Placenta post-gravidique de mammifère, son utilisation et céllules souches placentaires correspondantes
AU2011202711B2 (en) Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
NZ579705A (en) Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US20170224739A1 (en) Placental stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
AU2012200069B2 (en) Post-partum mammalian placenta, its use and placental stem cells therefrom
AU2007234581B2 (en) Post-partum mammalian placenta, its use and placental stem cells therefrom
AU2015203846A1 (en) Post-partum mammalian placenta, its use and placental stem cells therefrom

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040913

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1069738

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20051230

17Q First examination report despatched

Effective date: 20060811

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20100311

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1069738

Country of ref document: HK